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Abstract 
Introduction: All first-line anti-tuberculosis drugs can be associated with all phenotypes 
of cutaneous adverse drug reactions (CADR). Second-line drugs are associated with 
much poorer outcomes. Thus, identifying the offending drug in poly-pharmacy is difficult. 
Re-challenge with the drug is the gold standard in identifying the offender, however 
poses unacceptably high risk of CADR recurrence. Population and drug-specific 
genomics help identify those susceptible to adverse reactions to a drug facilitating 
avoidance of the drug. 
Objective: To investigate the genomic susceptibility in patients with confirmed 
rifampicin and or isoniazid-associated hypersensitivity reactions using both genome-
wide association studies and candidate gene approaches.  
Methods: A case control study using 14 patients with previous tuberculosis-associated 
CADR who were re-challenged with first-line anti-tuberculosis drugs and subsequently 
developed re-challenge reactions to either isoniazid or rifampicin as cases. These were 
compared with 30 controls who had tolerated rifampicin and isoniazid during the re-
challenge process (12 patients, Group 1a) and consecutive patients who had been on 
TB treatment for at least 12 weeks without developing any adverse drug reaction (18 
patients, Group 1b) and 200 black South Africans from the general population. HLA 
genotypes of the samples were determined by SeCore® HLA Sequence based typing 
(Invitrogen, Life technologies, USA), and potential ambiguities were resolved by 
sequencing-based typing.  
Results: We found HLA-B*58:02 (OR=3.6; 95% CI: 1.4-8.99) and HLA-DRB1*09:01 
(OR=15.3; 95% CI: 2.1-113.1) to be significantly more prevalent in patients who 
developed rifampicin and isoniazid-associated CADR as compared to black South 
African general population. However, we found no significant associations between HLA 
genotype and rifampicin/isoniazid-associated CADR when we compared the cases to 
our study controls that had tolerated rifampicin and isoniazid. HLA-B *58.02 was not 
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found to be statistically associated with HIV positive status (p=0.42) and DRESS 
phenotype (p=0.6279).The majority of our cases were black Africans. Approximately 
80% of our cases and controls were HIV-infected. DRESS/DIHS was the prevalent 
phenotype of CADR, accounting for approximately 80% of cases and controls.  
Discussion: To our knowledge, this is the first study to show an association between 
HLA-B*58:02 and HLA-DRB1*09:01 alleles and severe cutaneous adverse drugs 
reactions secondary to rifampicin and isoniazid in an African population. We identify 2 
candidate HLA alleles that need confirmation of their association in African patients who 
develop rifampicin or isoniazid-associated CADR in larger studies. The value of 
identifying candidate alleles could lead to CADR preventative screening prior to initiating 
anti-tuberculosis therapy in black South Africans. The HLA-B*58:02 noted in our cases 
and controls tolerant of the drugs might not be associated with CADR but could be a 
reflection of the HIV status and control in HIV-TB co-infected persons.  
Conclusion: HLA-B*58:02 and HLA-DRB1*09:01 may be associated with rifampicin 
and isoniazid-associated CADR .Alternately HLA-B*58:02 may be associated with HIV 
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1: Literature review and background to the study 
  
1.1. Tuberculosis 
Tuberculosis (TB) is a worldwide infectious disease, caused by Mycobacterium 
tuberculosis (MTB). Commonly MTB affects the lungs however other organs can also 
be affected dependent on the person’s ability to control the primary infection (Ghon 
focus). In 2013, there were 9 million people globally who developed TB. Of these, 
approximately 5.15 million were men, 3.3 million were women and 0.55 million were 
children. The majority of the reported TB cases were in Asia (56%) and Africa (29%) 
(World Health Organization 2014). South Africa was among the six countries with the 
highest absolute number of incident cases of TB with estimated absolute incident cases 
of 410000−520000 in 2013. The other countries were India (2.0 million–2.3 million), 
China (0.9 million–1.1 million), Nigeria (340 000−880000), Pakistan (370000−650000 ) 
and Indonesia (410000−520 000) (World Health Organization 2014). Considering 
incident rates, South Africa with 560 (776-980) new cases of TB per 100 000 population 
remained in the top ten countries with the highest estimated population based incidence 
rates for 2013. Eight of the top ten countries with high population based incidence rates 
were on the African continent whose people appear to carry the global population 
burden of TB (World Health Organization 2014). 
 
Tuberculosis is one of the leading causes of death in the developing world. Due to 
human immunodeficiency virus (HIV) infection and poor socio-economic conditions in 
these regions, global attempts to control TB have been minimally effective and the 
incidence continues to increase (Department of Health Repulic of South Africa 2014). In 
2013 there were 1.5 million estimated TB deaths. Approximately 60% (900 000) of 
those dying from TB were men, 510 000 were women and 90 000 were children. 
African, South East Asian and Western Pacific WHO regions accounted for more than 
75% of the TB deaths (World Health Organization 2014).This data excludes cases that 
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were missed by the notification health system, mainly in the developing world. It is 
evident from these statistics that TB remains one of the major threats to global health. 
The HIV pandemic has resulted in a steep increased trajectory of cases co-infected with 
TB worldwide. Of the 9 million TB cases reported in 2013, 1.1million (13%), were co-
infected with HIV. Africa was the WHO region with the highest number of TB cases 
living with HIV (World Health Organization 2014). It was estimated that approximately 
34% of TB cases were co-infected with HIV in Africa, accounting for 78% (800 000) of 
TB-HIV co-infection worldwide (World Health Organization 2014). WHO data show that 
1.5 million people died from TB in 2013, and 360 000 (24%) of these deaths were in 
people who were co-infected with HIV (World Health Organization 2014). Despite 
constituting only 0.7% of the world’s population, South Africa accounts for about 25% 
(300 000) of the estimated global caseload of HIV associated TB (Wood et al. 2011). 
The annual risk of acquiring TB in an HIV infected individual is 10% compared to a 
lifetime risk of 10% in an HIV-unaffected counterpart (Department of Health Repulic of 
South Africa 2014). Infection with HIV increases the risk of dissemination of recent MTB 
infection and of reactivation of latent MTB infection by 5 to 15% annually (Department of 
Health Repulic of South Africa 2014). 
The burden of HIV and TB co-infection has resulted in multiple new TB management 
problems, including an increase in reported cases of multi drug resistance (MDR) TB. 
Wells and colleagues reported the association of HIV and (MDR) TB which resulted in 
complexity in the management of TB patients and hence poor infection control (Wells et 
al. 2007). The risk factors in HIV and TB co-infected patients for developing MDR TB 
were advanced immunosuppression, poor adherence to first line TB medication 
including the intermittent use of TB treatment, drug interactions, adverse drug reactions 
and poor gastrointestinal absorption of TB drugs (Wells et al. 2007). 
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1.2. Adverse drug reactions 
There are various definitions for what constitutes an adverse drug reaction (ADR). In 
1998, Pirmohamed and colleagues defined ADR as ‘unpleasant effects of the drug 
beyond its expected therapeutic effects which occur during clinical use (Pirmohamed et 
al. 1998).The term adverse drug effect (ADE) and ADR are often used interchangeably 
to mean the same thing but the ADE is the expected effect of the drug and an ADR is 
an unexpected reaction that occurs in a patient (Aronson & Ferner 2005). 
Adverse drug reactions were initially divided into type A (augmented pharmacology) or 
type B (bizarre, idiosyncratic).Type A (Augmented) reactions represent an augmentation 
of the pharmacological actions of a drug. They are predictable, dose dependent and are 
therefore readily reversible on reducing the dose or withdrawing the drug. Type A 
reactions account for the majority of ADRs and includes side effects and toxic effects. 
Type B (Bizarre) reactions in contrast are rare, bizarre, unpredictable and are not dose 
dependent nor related to known drug pharmacology. They include immune mediated 
hypersensitivity reactions (IgE-mediated urticaria and immune complex vasculitis) and 
idiosyncratic reactions which are severe and life threatening such as SJS/TEN and 
DRESS where the pathogenesis is not clear-cut. 
The importance of time-dependent reactions that occur after prolonged or chronic use, 
on drug withdrawal, or with a delayed action relative to when the drug was used need 
additional classification groups, as does drug failure. Type C (Chronic) reactions are 
related to time on medication and cumulative dose (glucocorticoid suppression of 
hypothalamic-pituitary-adrenal axis by glucocorticoid). Type D (Delayed) reactions 
becoming apparent sometime after the use of the drug and include teratogenesis and 
carcinogenesis. They are often dose-related. Type E (Withdrawal) reactions occur when 
the drug is withdrawn for whatever reason. Type F (Failure) reactions occur because of 
drug interactions leading to failed therapy. They are dose related(Todd 2006; Edwards 
& Aronson 2000).ADR are usually diagnosed on clinical grounds from the temporal 
relation between the start and finish of drug treatment and the onset and resolution of 
the reaction. A culprit drug is identified if the signs and symptoms of ADR occurred after 
initiating the drug and resolves after withdrawing the drug and recur again on re-




Adverse drug reactions contribute substantially to patient morbidity and hospitalization 
in South Africa. This is added to by the burden of HIV and TB co-infection. A South 
Africa study showed that HIV-uninfected persons are less likely to be admitted to 
hospital with adverse drug reactions compared to those who are HIV-infected (Mehta et 
al. 2008). Polypharmacy (more than 7 drugs) commonly ARVs, anti -tuberculosis drugs 
and co-trimoxazole were the main implicated drugs in most of the ADR admissions and 
deaths in four South African hospitals (Mouton et al. 2014). Mouton and colleagues  
reported drug induced renal failure and drug-induced liver injury were the most common 
adverse drug reactions related to death in HIV patients admitted to hospital for ADRs in 
the same survey of the 4 hospitals in South Africa (Mouton et al. 2014). Of the 24 
patients who developed drug-induced renal failure, tenofovir was the most commonly 
implicated culprit drug in 14 (61%) cases followed by co-trimoxazole in 3 cases, 
rifampicin in 2 cases, furosemide in 2 cases, co-amoxiclavulanic acid in 2 cases and 
ibuprofen, enalapril, spironolactone, ciprofloxacin, aciclovir and indomethacin 1 case 
each. Ten patients developed drug-induced liver injury. Seven cases were due to anti 
TB drugs (rifampicin, isoniazid and/or pyrazinamide) and 3 cases were due to co-
trimoxazole either alone or together with other drugs. Fluconazole, erythromycin and 
sodium valproate accounted for 1 case each (Mouton et al. 2014). This data reflects the 
significant role played by anti-tuberculosis drugs in HIV associated ADR.  
 
1.3. Cutaneous adverse drug reactions  
A cutaneous adverse drug reaction (CADR) is the skin manifestations of an adverse 
drug reaction. There are different phenotypes of CADR ranging from mild self-resolving 
reactions to severe life threatening ones. Essentially any skin disease can be a 
manifestation of an adverse cutaneous reaction. Among the milder phenotypes are, 
exanthematous drug eruptions; IgE mediated reactions like urticaria; photo accentuated 
drug reactions; classic fixed drug reaction; vasculitis; neutrophilic drug reactions like 
acute generalized exanthematous pustulosis (AGEP) and acute febrile neutrophilic 
dermatoses (Sweet’s syndrome). The severe or life threatening drug reactions include 
drug reaction with eosinophilia and systemic symptoms (DRESS) also referred to as 
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drug induced hypersensitivity syndrome (DIHS); generalized bullous fixed drug 
eruptions (GBFDE); Stevens-Johnson syndrome (SJS); toxic epidermal necrolysis 
(TEN) and lichenoid drug reactions (LDR). 
 
Exanthematous, maculopapular or morbilliform drug reactions mostly occur 7 to 14 days 
after starting medications or earlier in cases of re-introduction of the same offending 
medication. Clinically they presents with an erythematous, maculopapular, measles-like 
eruption (Figure 1), urticarial plaques or annular, targetoid lesions. The mucosal 
surfaces are spared. The rash resolves within one or two weeks with no systemic 














Figure 1: Morbilliform rash 
 
Urticaria (Figure 2) is characterized by transient, erythematous, infiltrated papules and 
plaques with no epidermal change. The lesions last for less than 24 hours and resolve 
with no epidermal or post inflammatory changes. Angioedema (Figure 3) is acute 
oedema of dermal, subcutaneous and mucosal tissues and can be life-threatening if 
associated with asphyxia. Anaphylaxis is an acute life threatening type I hypersensitivity 
or IgE dependent drug reaction characterized by systemic manifestations including 
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hypotension and tachycardia which may occur together with or without urticaria and 
















Figure 3: Angioedema 
 
Photosensitivity drug reactions (Figure 4) could either be photo-toxic (non-immune) or 
photo-allergic (immune mediated). The regions of the body affected are the sun-
exposed surfaces of the face (forehead, zygoma, nose, lower lip and chin), the ears and 
cervical triangle. Sparing of the submental, posterior auricular and periorbital regions is 
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strongly supportive. Photo-toxic drug reactions usually occur within hours after exposure 
to the culprit drug together with light. This clinically resembles exaggerated or acute 
sunburn and can occur in any person taking a drug known to cause phototoxic 
reactions. Photo-allergic drug reactions usually develop within days of exposure to the 
culprit drug together with ultraviolet radiation. They are type IV hypersensitivity reactions 
and clinically may resemble eczema or lichenoid reactions (Glatz & Hofbauer 2012). 
 
   
Figure 4: Photosensitivity drug reaction 
 
Lichenoid drug reactions (LDR) occur within months to years of exposure to the culprit 
drug but may require exposure to the culprit drug together with ultraviolet radiation. It is 
clinically characterised by burning, itchy, lilac macules that progresses to become 
violaceous to purple, flat-topped, scaly papules often involving the flexural surfaces. 
Both the skin and mucosae may be involved. It resolves with or without post 

















A fixed drug eruption may occur on the skin or mucosae within minutes of culprit drug 
ingestion. They clinically presents as an itchy, well circumscribed, round, erythematous 
to purple patch often with an outer rim of erythema in the active state. They can blister 
and they resolve leaving slatey grey-black post-inflammatory hyperpigmentation (Figure 
6). They occur as solitary or multiple patches. Re-exposure to the offending drug leads 
to recurrence at the same site or the development of new lesions elsewhere. 
Occasionally it can be life-threatening and confused with SJS/TEN if it is bullous and 











Figure 6:  Figure 7: 




SJS and TEN are severe, potentially life threatening drug reactions that occur between 
one to two weeks after exposure to the culprit drug. They are clinically characterized by 
mouth, eyes and genitalia involvement together with epidermal necrosis and varying 
degrees of detachment on a background of erythema. In SJS, the skin detachment is 
<10% body surface area (BSA) (Figure 8) compared to >30% BSA in TEN (Figure 9). 
SJS/TEN overlap is characterized by epidermal necrosis of 10%-30% (Roujeau 1994). 
SJS and TEN may be associated with systemic disease or with complications that could 
either be acute or chronic. Acute complications that account for the high mortality 
include bacterial systemic infection, metabolic dysfunction and fluid loss. Mortality risk 
can be assessed on the day of admission and again 3 days later by applying the TEN-
specific severity-of-illness score (SCORTEN) (Guégan et al. 2006). Nail dystrophies, 
dyspigmentation, sicca symptoms, mucosal adhesions, oesophageal strictures, 
hypertrophic scars and blindness are chronic anticipated sequelae in some cases 
especially in those with severe disease (Roujeau 1994) . 
The mortality rate varies. Studies have shown that SJS mortality ranges between 0% 
and 12%, while that of TEN ranges from 30% to 46% (Sekula et al. 2013; Saka et al. 
2013; Kannenberg et al. 2012; Roujeau & Stern 1994). The mortality rate may increase 
depending on the extent of the BSA involved, the patient’s age and other SCORTEN 
parameters (Harr & French 2010). A large prospective cohort study of severe SJS/TEN 
requiring hospitalization from several centres in Europe, reported a 6 week mortality 
rate of 23% overall; 12% for SJS, 29% for SJS/TEN overlap and 46% for TEN (Sekula 
et al. 2013). In this study a history of malignancy and the older age of the affected 
patients contributed to the higher mortality reported. In a prospective cohort study 
undertaken in South Africa, a comparable mortality rate of 24% for all forms of SJS and 
TEN was reported. When sub analysis were done, the TEN mortality rate was 40% 
which was statistically significant (p=0.001) when compared to the 0% of SJS 
(Kannenberg et al. 2012). Comparable findings were reported for sub-Saharan Africa in 
a retrospective study of a cohort collected from several African countries in which 74% 
were less than 50 years of age. An overall mortality of 12% was found; 5% for SJS, 9% 
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for SJS/TEN overlap and 41% for TEN. HIV-infection was comorbidity in 73% of the 22 













Figure 8: Stevens-Johnson syndrome      Figure 9: Toxic epidermal necrolysis 
 
DRESS/DIHS is a severe CADR which occurs two to six weeks after exposure to the 
offending drug. It is clinically characterized by fever, oedema (especially of the face), a 
morbilliform rash (Figure 10), lymphadenopathy, leukocytes abnormalities and internal 
organ involvement. The most commonly affected internal organ is the liver which may 
result in severe hepatitis, liver failure, encephalopathy and sometimes death. A mortality 
rate for DRESS/DIHS was reported to be 10% from RegiSCAR data from around the 



























2.1. Adverse drug reaction pathogenesis 
Multiple factors influence the occurrence of disease, its clinical picture and outcome. 
This concept best explains the pathogenesis of unexpected reactions to drugs. Only a 
proportion of those exposed to an infectious agent will develop clinical disease, and 
similarly not all those exposed to a drug develop a drug reaction. Other cofactors of 
causation need to be variably present, which, on their own, do not necessarily produce 
the effect (Todd 2006; Sullivan & Shear 2001) 
The pathogenesis of CADRs is slowly unraveling. The mechanism by which a drug 
leads to immune mediated adverse reaction (pharmaco-immune concept, modified Gel 
and Coombs hypersensitivity reactions) can be explained by either hapten hypothesis or 
P I concept. The drug or its metabolites must be recognized by the immune system in 
the context of self. Several mechanism have been shown to be involved in drug/major 
histocompatibility complex (MHC)-peptide binding on antigen-presenting cells for 
initiation of an immune response, both innate and adaptive and cause localized or 
systemic reactions. The drug acts as a hapten (the chemically reactive drug itself binds 
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covalently to carrier proteins which may include the MHC-peptide complex), prohapten 
(the drug must be metabolised to a reactive hapten) and non-hapten (non-covalent, 
labile binding to the MHC-peptide complex) or the p-I concept (pharmacological 
interactions of drug with immune receptors concept, drugs can bind directly to T-cell 
receptors TCR). On presentation or binding to T-cells via shared or restricted TCRs 
(HLA-drug-TCR interaction), multiple cellular triggers are required for the propagation of 
an immune response resulting in an expansion of lymphocyte clones (T and B cells), the 
releases of cytotoxic proteins (granulysin, perforin, granzyme etc.), and 
apoptosis(Pichler et al. 2010). All reactions are T-cell–regulated, but the effect is 
dependent on antibody-mediated effector functions or more T-cell/cytokine dependent 
functions.(T and B cells) and cause localized or systemic reactions The “danger” 
hypothesis  proposes that following initiation of the acquired immune system, tolerance 
(possibly involving T-reg cells) is the normal default response and that “danger” signals 
are necessary for propagation and the subsequent development of an immune 
response. “Danger” signals can be produced by the innate immune system or any 
inflammatory episode as a result of cellular stress (e.g., drug/toxic metabolites, cell 
damage, bacterial products) (Todd 2006; Uetrecht 1999). 
The cutaneous reactions that can occur as a result of immune stimulation by a single 
drug are influenced by the efferent output following T-cell activation. Preferential 
activation of T-cell populations with distinct functions can lead to cytotoxic T-cells (CD4+ 
cells in morbilliform reactions, CD8+ cell in vesico-bullous reactions) can orchestrate the 
skin reaction by release of cytokines/chemokines which in turn activate or recruit 
specific cells into the skin (interleukin 4 and 5 for eosinophil infiltrates, interleukin 8 for 
neutrophil infiltrates, interferon-γ for monocyte infiltrates) (Pichler et al 2010). 
The dynamic synergistic interaction of constitutional and acquired factors, determines 
whether one develops a drug reaction. The unique combination of cofactors present at 
the time of drug exposure in a particular individual may explain why an adverse event 





The relationship between drug reactions and immunogenetics was recently proposed by 
Chung and colleagues who showed that certain polymorphisms of the HLA genes 
predispose to drug hypersensitivity reactions. These included HLA-B*15:02 and 
carbamazepine (CBZ)-induced SJS/TEN and HLA-B* 58:01 and allopurinol-induced 
SJS/TEN and DRESS (Chung et al. 2007). More recent studies have shown that drugs 
presented by specific HLA alleles are recognized by specific T cell receptors leading to 
activation of cytotoxic T lymphocytes and cytotoxic signal expression (Chung et al. 
2008). These HLA genetic associations with immune-mediated cutaneous drug 
reactions are complex, drug specific and ethnicity specific. 
 
HLA-B*15:02 has been shown to be present in 100% of Han Chinese who develop 
CBZ-induced SJS/TEN but in only 3% of CBZ-tolerant patients and in 8.6% of the 
general population of Han Chinese from Taiwan (Hung et al. 2006; Chung et al. 2004). 
HLA-B*15:02 is present in 75% of Malay patients with CBZ-induced SJS/TEN but in 
only 15.7% of normal controls (Chang et al. 2011). In a study done in Europe only four 
cases (25%) were HLA-B*15:02 allele positive among 12 cases of CBZ-induced 
SJS/TEN and all four were of Asian origin (Lonjou et al. 2006). Screening for HLA-
B*15:02 before prescribing CBZ in Taiwan has significantly reduced the number of 
cases of SJS/TEN in the country (Ferrell & McLeod 2008) .This is probably applicable 
for Malaysia and for Asians living abroad. 
 
HLA-B*58:01 was reported to be present in all 51 patients (100%) with allopurinol-
induced SJS/TEN and DRESS in Han Chinese but in only 15% (20 of 135) of the 
allopurinol tolerant group and 20% (19 of 93) of the general healthy population from 
Taiwan (Hung et al. 2005). In Thai population, twenty seven (100%) allopurinol-induced 
SJS/TEN patients who were examined carried HLA-B*58:01 whereas only seven (13%) 
of the tolerant control patients had this allele (Tassaneeyakul et al. 2009). 
 
HLA-B*57:01 was reported as present in 14 (78%) of the 18 patients with abacavir 
hypersensitivity, and in four (2%) of the 167 abacavir tolerant patients from a Western 




The presence of HLA-B*13:01 was proposed as a predictor of dapsone hypersensitivity 
in patients with leprosy. It was present in about 2% to 20% of Chinese persons with 
leprosy and dapsone hypersensitivity reactions, 1.5% of a similar cohort in Japan, 1% to 
12% of Indians with leprosy and dapsone hypersensitivity, and 2% to 4% of a similar 
Southeast Asian cohort but 0% in European and African cohorts (Zhang et al. 2013). 
 
Clearly there are population, drug and CADR specific HLA haplotypes that are not 
generalizable globally. 
 
2.2. Pathogenesis of adverse reactions to TB drugs 
Sharma and colleagues have demonstrated the association of HLA class II haplotypes 
associated with anti-tuberculosis drug induced liver injury. These include HLA-DRB1*03 
for isoniazid, HLA-DQA1*01:02 for rifampicin, and HLA-DQB1*02:01 for ethambutol 
(Sharma et al. 2005). 
 
Other studies have shown the association between isoniazid-induced hepatitis and 
genetic polymorphisms of drug metabolism enzymes, including cytochrome P450 2E1 
(CYP2E1), N-acetyltransferase 2 (NAT2), and glutathione-S-transferase (GST) M1 
(GSTM1). Individuals with CYP2E1 gene activity are able to convert isoniazid to toxic 
metabolites, including hydrazine, while GSTM1 and NAT2 convert the toxic metabolites 
to non-toxic metabolites (Huang et al. 2002). Huang and colleagues reported 
polymorphisms of the NAT2 gene as a susceptibility risk factor for anti-tuberculosis 
drug-induced hepatitis. N-acetyltransferase 2 is responsible for acetylation of INH toxic 
metabolites. Polymorphisms promoting slow acetylators have a more than two-fold risk 
of developing INH-induced hepatitis when compared with fast acetylators in a 
Taiwanese population (Huang et al. 2002). The following risk factors for the 
accumulation of hydrazine, the toxic metabolite of isoniazid, have been reported by 
Fukino and colleagues and include NAT2 slow acetylator phenotype, high concentration 




The clinical presentation of TB-associated CADR varies with different studies 
elaborating different types of CADR due to TB drugs. Tan and colleagues reported on 
47 patients who developed TB associated CADR. A morbilliform eruption was seen in 
72.3%, 8.5% had urticaria and the rest developed exfoliative dermatitis, erythema 
multiforme and a lichenoid eruption (Tan et al. 2007). Lehloenya and colleagues 
reported on the spectrum of TB-medication associated severe CADR requiring hospital 
admission. The spectrum of CADR included DIHS/DRESS (38%), SJS (26%), TEN 
(20%), SJS/TEN overlap (8%), and lichenoid drug reactions (5%) (Lehloenya et al. 
2011). In a study from Togo, among 8 cases of severe CADR due to rifampicin and 
isoniazid, 3 developed SJS and 5 developed TEN (Pitche et al. 2005).  
 
The clinical presentation of anti-tuberculosis associated drug reactions is likely to be 
immune-mediated, since re-challenging with the same drug typically shortens the 
incubation period and results in more severe manifestations (Hung et al. 2006; Chung et 
al. 2004). 
 
The CADR are more frequent to occur in HIV infected patients compared to un-infected 
person. A South Africa study showed that HIV-uninfected persons are less likely to be 
admitted to hospital with adverse drug reactions compared to those who are HIV-
infected (Mehta et al. 2008). Polypharmacy (more than 7 drugs) commonly ARVs, anti -
tuberculosis drugs and co-trimoxazole were the main implicated drugs. There is a high 
incidence of TB-associated severe CADR in HIV-infected patients in the South African 
population (Marks et al. 2009). A study from a primary care clinic in South Africa 
showed that severe CADR to anti-tuberculosis drugs occurred in 13% of non-HIV-
infected patients and 27% of those who were HIV-infected (Marks et al. 2009). 
Lehloenya and colleagues reported that 92% of the severe TB-associated CADR 
admitted to a tertiary hospital in South Africa from January 2001 to April 2009 were HIV 






3. Tuberculosis management 
First line anti-tuberculosis therapy with rifampicin (RIF), isoniazid (INH), pyrazinamide 
(PZA) and ethambutol (EMB) is effective with excellent cure rates and results in less 
recurrence of TB after treatment (Rezakovic et al. 2014). However it is associated with 
CADRs. Several studies demonstrate a significant increase of TB CADRs due to the 
increased burden of TB co-infected HIV individuals requiring treatment. From a 
retrospective study done in Penang hospital an incidence rate of 5.7% for CADRs was 
reported. Pyrazinamide was the commonest offending drug (2.38%), followed by 
streptomycin (1.45%), ethambutol (1.44%), rifampicin (1.23%) and isoniazid (0.98%) 
(Tan et al. 2007). CADRs were more likely to occur in HIV-infected people with 
polypharmacy(>7 drugs) and those with autoimmune disorders (Tan et al. 2007). In a 
similar retrospective study done in South Africa, among patients admitted to hospital 
with severe CADRs, rifampicin was the most commonly implicated drug, followed by 
isoniazid, pyrazinamide and lastly ethambutol. Respectively these drugs were 
responsible for 57%, 22%, 13% and 4 % of severe CADRs (Lehloenya et al. 2011). 
 
Adverse drug reactions caused by anti-tuberculosis drugs can lead to interruption of 
therapy, treatment failure and/or the risk of drug-resistance (Rezakovic et al. 2014). 
Drug resistance complicates the management of tuberculosis and represents one of the 
most important emerging challenges in the control of TB worldwide (Glaziou et al. 
2013). 
 
The consequences of TB-associated CADR are thus significant and include increased 
mortality and morbidity and the need for second line anti-tuberculosis therapy. 
 
Second line anti-tuberculosis therapy is associated with a higher incidence of toxicities 
and is less effective (Rezakovic et al. 2014). Despite this, it is still considered as a 
treatment option for multidrug resistance TB and repeat infections. These second line 
anti-tuberculosis drugs are associated with their own range of severe CADRs. They are 
also associated with multiple drug hypersensitivity reactions which pose a major long 
term therapeutic challenge when needed for patients with proven allergies to first line 
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agents. In a study from South Africa among patients admitted with CADRs, 
streptomycin and ofloxacin were related to multiple drug hypersensitivity CADRs in 4% 
(1/23) of the cases each (Lehloenya et al. 2011).  
 
Switching to second line anti-tuberculosis treatment results into poorer compliance due 
to the anxiety of taking treatment after experiencing a severe CADR together with the 
longer duration of treatment required to achieve cure and the higher side effect profile in 
comparison to first-line agents (Rezakovic et al. 2014). 
 
As a consequence of significant adverse health effects, suboptimal treatment and poor 
outcome associated with the use of the second line treatment, there is a need for re-
challenge to identify the offending drug and remove it from the primary treatment 
regimen. Despite the associated risks of a recurrence of a severe CADR, first line 
treatment is necessary as it provides better infection control. Ultimately the balance 
between the benefit of re-exposure and risk of severe CADR and suboptimal treatment 
has to be weighed before re-challenge (Lehloenya & Dheda 2012; Lehloenya et al. 
2011). 
 
4. Drug causality and re-challenge 
Clinical assessment is commonly used to indicate the causality of ADRs if there is a 
history of a recent new drug having been administered. Establishing drug causality 
becomes very difficult when there is more than one drug administered at the same time 
such as with TB drugs or when there is polypharmacy in cases of multiple co-
morbidities such as HIV-TB co-infection. In these settings there is a need to test for drug 
causality. 
 
There are various methods of determining drug causality. These modalities could either 
be performed in vivo or in vitro. In vitro tests includes lymphocyte transformation 
test/assay (LTT/LTA), CD69 up-regulation flow cytometry test and cytokine production 
assays. LTT/LTA is one of the most widely used laboratory tests for the identification of 
the culprit drug following ADR/CADR. The sensitivity and specificity of LTT/LTA varies 
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with the drug being evaluated, experience of the laboratory technicians performing the 
test, type of CADR being investigated and the subject (Pichler & Tilch 2004). 
Lochmatter and colleagues reported that, LTT/LTA has a low specificity of 85% and 
sensitivity (60-70%) in comparison to other methods such as oral provocation test 
(Lochmatter et al. 2009). Suzuki et al evaluated the usefulness of LTT/LTA for 
determining the offending anti-tuberculosis drugs causing side effects in comparison to 
the gold standard (oral provocation test). They reported that the sensitivity of LTT/LTA 
was only 14.9% in identifying the offending anti-tuberculosis drugs. (INH 14.3%, RIF 
13.6%, EMB 14.3%, PZA 0%) (Suzuki et al. 2008). Despite being used for more than 30 
years LTT/LTA is still considered experimental due to its limitations. 
 
In vivo modalities are the oral provocation test and skin testing (patch, prick and 
intradermal). These are re challenge procedures where the patient is re-exposed or re-
introduced to the drug which previously caused the adverse drug reaction.  
 
Oral provocation test also known as controlled challenge, re-exposure test, and drug re-
challenge test is the controlled administration of a drug in order to diagnose drug 
reaction causality. It could entail either the administration of the offending drug per se or 
a structurally or pharmacologically related compound (Aberer et al. 2003). Oral 
provocation testing remains the “gold standard” in establishing drug causality relative to 
a specific ADR (Kurniadhi et al. 2006).  
 
An oral provocation test has its own limitations and a negative provocation does not 
completely prove tolerance in the future or exclude the drug as the culprit if other 
associated co-factors and comorbidities are absent during the oral challenge or if it is 
done at too low a dose and not over a long enough period of time. A positive 
provocation test similarly might not indicate lifelong hypersensitivity for similar reasons. 
The severity of CADR recurrence is also not predictable (Aberer et al. 2003).  
 
In our cases and controls re-challenge followed a specific protocol in which the patients 
underwent serial testing (patch, skin prick and then oral) over a 2 week period. If any 
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test caused a reaction re-challenge was halted. If there was no reaction the patient was 
maintained on the drug to which they had been re-challenged for the period of the TB 
treatment. This re-challenge was not done for academic reasons but to re-introduce the 
best medication for controlling TB especially in immunosuppressed patients.  
 
Skin testing with the suspected offending drug may be useful in determining the cause 
of a CADR. This could either be in the form of a patch, prick or intradermal test. These 
tests also pose a risk of eliciting the initial CADR. It is postulated that the severity of the 
re-challenge reaction should be less severe compared to oral re-challenge as there is 
exposure to lower concentrations the offending drug. This is not proven to be the case 
in clinical practice. Shebe and colleagues reported recurrence of drug reaction with 
eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in 
a human immunodeficiency virus-infected man (Shebe et al. 2014). 
 
Skin test sensitivity (70%) and specificity is still low especially in non-immediate 
reactions even when used in its maximum concentration compared to oral provocation 
testing (Rerkpattanapipat et al. 2011). 
 
Genes that control the immune response in humans, especially those within the major 
histocompatibility complex, have been shown to modulate the expression of diseases 
induced by exogenous triggers (infections, foreign protein, environmental allergens or 
medication)(Miura et al. 2009; O’Connell et al. 2009; Louie et al. 2004).The human 
genome, mainly HLA, has been well documented to have a role in modulating infectious 
diseases such as TB and HIV (Louie et al. 2004). HLA class I and II ( HLA-B8, HLA-B15 
and HLA-DR2) have been shown to be associated with a risk of active TB while a HLA-
DR6 association decreases the risk of TB (Louie et al. 2004). HLA class I has been 
associated with HIV control and progression. HLA-B* 58:01 reduces viral load 
replication and induces cytotoxic T cell lymphocyte response in HIV-infected persons 
and is associated with good prognosis. HLA-B*58:02 is associated with rapid 





At present there is no practical screening test to identify those susceptible to 
tuberculosis drug-associated reactions and the susceptibility genes remain unknown. 
Various studies have shown immunogenetics to be population and drug specific (Chung 
& Hung 2012). We have a well characterized confirmed severe CADR population in 
Cape Town. The culprit drug has been confirmed through patch and/or prick testing 
and/or oral drug re-challenge. They are an ideal population cohort to investigate the 
immunogenetics of anti-tuberculosis drug-associated CADR. 
 
Challenges to this study will be to tease out the HLA contributions of HIV and TB to our 
findings. The use of a group of drug tolerant patients who also have HIV and TB we 
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All first-line anti-tuberculosis drugs can be associated with all phenotypes of cutaneous 
adverse drug reactions (CADR). Second-line drugs are associated with much poorer 
outcomes. Thus, identifying the offending drug in poly-pharmacy is difficult. Re-
challenge with the drug is the gold standard in identifying the offender, however poses 
unacceptably high risk of CADR recurrence. Population and drug-specific genomics 
help identify those susceptible to adverse reactions to a drug facilitating avoidance of 
the drug. We aimed to investigate the genomic susceptibility in patients with confirmed 
rifampicin and or isoniazid-associated hypersensitivity reactions using both genome-
wide association studies and candidate gene approaches. There were no significant 
candidate genes between our cases and study controls. However, when compared to 
the general population of black South Africans, HLA-B*58:02 (OR=3.6; 95% CI: 1.4-
8.99) and HLA-DRB1*09:01 (OR=15.3; 95% CI: 2.1-113.1) were significantly more 
prevalent among our cases. HLA-B*58:02 and HLA-DRB1*09:01 may be associated 
with rifampicin and isoniazid-associated CADR. Alternately HLA-B*58:02 may be 
associated with HIV status rather than CADR. A sufficiently powered study is needed to 


















Tuberculosis (TB) is a common worldwide infectious disease. In 2013, 9 million people 
globally developed TB. South Africa had the 6th highest estimated incidence rate of TB 
(410000−520000 per 100 000 population). TB is a leading cause of mortality in the 
developing world, particularly in populations with a high HIV burden. In 2013 
approximately 13% of the 9 million cases worldwide were HIV co-infected (World Health 
Organization 2014). The pandemic of HIV and TB co-infection has resulted in multiple 
new problems, including a higher incidence of cutaneous adverse drug reactions 
(CADR). The offending drugs often include anti-retroviral drugs, anti-tuberculosis drugs 
and other drugs used for management of HIV-associated opportunistic infections 
(Mouton et al. 2014; Marks et al. 2009; Mehta et al. 2008; Pozniak et al. 1992). 
TB-associated CADRs range from mild, self-resolving to severe and life threatening 
reactions. Some are severe enough to warrant interruption of therapy, such as drug 
reaction with eosinophilia and systemic symptoms also called drug induced 
hypersensitivity syndrome (DRESS/DIHS); Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN) (Lehloenya & Dheda 2012). 
Recent studies have shown that drugs, presented by specific human leukocyte antigen 
(HLA) alleles, are recognized by specific T cell receptors leading to activation of 
cytotoxic T lymphocytes and cytotoxic signal expression (Chung et al. 2008). These 
HLA genetic associations with immune-mediated cutaneous drug reactions are 
complex, drug specific and ethnicity specific. HLA-B*15:02 is found in 100% of Han 
Chinese who develop carbamazepine (CBZ) -induced SJS/TEN (Hung et al. 2006; 
Chung et al. 2004). It is also found in 75% of Malay patients with CBZ-induced SJS/TEN 
(Chang et al. 2011). HLA-B*58:01 is found in 100% of Han Chinese with allopurinol 
cutaneous adverse drug reaction including SJS/TEN and DRESS (Hung et al. 2005). 
HLA-B*5701 is found in 78% of the Western Australian cohort with abacavir 
hypersensitivity (Mallal et al. 2002). HLA-B*13:01 is a predictor of dapsone 
hypersensitivity in Chinese persons with leprosy (Zhang et al. 2013).  
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Sharma and colleagues have demonstrated the association of HLA class II haplotypes 
associated with anti-tuberculosis drug induced liver injury. These include HLA-DRB1*03 
for isoniazid, HLA-DQA1*01:02 for rifampicin, and HLA-DQB1*02:01 for ethambutol 
(Sharma et al. 2005). Other studies show the association between isoniazid-induced 
hepatitis and genetic polymorphisms of drug metabolism enzymes, including 
cytochrome P450 2E1, N-acetyltransferase 2 (NAT2), and glutathione-S-transferase M1 
(GSTM1) (Huang et al. 2002). Fukino and colleagues included NAT2 slow acetylator 
phenotype, high concentration of serum rifampicin, and GST M1 null genotype as risk 
factors for anti-tuberculosis-induced hepatitis (Fukino et al. 2008). 
First line anti-tuberculosis therapies, while effective; are associated with CADRs 
(Rezakovic et al. 2014). Lehloenya and colleagues  reported that the spectrum of TB-
associated severe CADRs which required admission in South Africa included 
DIHS/DRESS (38%), SJS (26%), TEN (20%), SJS/TEN overlap (8%), and lichenoid 
drug reactions (5%) (Lehloenya et al. 2011). Among these patients, rifampicin was the 
most commonly implicated drug, followed by isoniazid, pyrazinamide and lastly 
ethambutol. Respectively these drugs were responsible for 57%, 22%, 13% and 4 % of 
CADRs (Lehloenya et al. 2011). 
A study done in a primary care clinic in South Africa reported that CADRs to anti-
tuberculosis drugs occurred in 13% of non-HIV-infected patients and 27% of those who 
were HIV-infected (Marks et al. 2009). Lehloenya and colleagues  also reported a high 
association, 92% of severe TB-associated CADRs admitted between January 2001 and 
April 2009 were HIV co- infected patients (Lehloenya et al. 2011). 
Adverse drug reactions caused by anti-tuberculosis therapy can lead to interruption of 
therapy, treatment failure and/or the risk of drug-resistance (Rezakovic et al. 2014).The 
consequences of TB-associated CADRs are thus significant and include increased 
mortality and morbidity and hence the need for second line anti-tuberculosis therapy. 
Second line anti-tuberculosis therapy is less effective, has a higher incidence of 
toxicities (Rezakovic et al. 2014) and their own range of severe CADRs. As a 
consequence of significant adverse health effects, suboptimal treatment and poor 
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outcome associated with the use of the second line therapy, there is a need for re-
challenge to identify the offending first line drug and remove it from the primary 
treatment regimen. Despite the associated risks of a recurrence of a severe CADR, first 
line treatment is necessary as it provides better infection control. Ultimately the balance 
between the benefit of re-exposure and risk of severe CADR and suboptimal treatment 
has to be weighed before re-challenge (Lehloenya & Dheda 2012; Lehloenya et al. 
2011). 
At present there is no practical screening test to identify those susceptible to 
tuberculosis drug-associated reactions and the susceptibility genes remain unknown. 
Various studies have shown immunogenetics to be population and drug specific (Chung 
& Hung 2012). We have a well characterized, confirmed severe CADR population in 
Cape Town. The culprit drug has been confirmed through patch and/or prick testing 
and/or oral drug re-challenge. They provided an ideal population cohort to investigate 
the immunogenetics of anti-tuberculosis drug-associated CADRs. 
 
RESULTS  
Demographic characteristics (Table 1) 
We recruited a total of 44 participants for this study. The 14 cases all had re-challenge 
reactions to either RIF and/or INH. The 26 controls tolerated these drugs and comprised 
12 patients with anti-tuberculosis drug-associated CADRs tolerant to RIF and INH on re-
challenge (Group1a) and 18 cases with no CADRs but on TB medication (Group 1b).  
The median age of our study population was 35 years with cases 32 years and controls 
36years (Group1a, 35 years and Group1b 36 years).There were more females amongst 
the cases (57%) compared to the controls (43% overall; Group1a, 50%; Group1b 39%). 
The majority of the patients were black, 31/44 (70%) and the remaining 13/44 (30%) 
were of mixed race origin. This ratio was similar for cases and both control groups.  
Most of the study cohort was HIV positive accounting for 82% of patients. Eleven out of 
14 (79%) cases were HIV-infected as were 25/30 (83%) of the controls. All 12 (100%) of 
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control Group1a were infected compared to only 13/18 (72%) of control Group1b. The 
median CD4 count of those cases who were HIV-infected was 149cells/mm3 (range: 74-
329) and it was 171cells/mm3 (range: 76-323) among controls although Group1b, 300 
cells/mm3 (range 124-333) had a higher median CD4 count compared to Group 1a, 108 
cells/mm3 (range 39-141). Less than 50% of those who experienced CADRs were on 
ARVs (42% cases and 43% Group 1a controls).Seventy-two percent of those on TB 
medication who had not experienced CADRs (Group 1b) were on ARVs. 
Clinical characteristics:  
None of the cases or controls had a history of ADRs to any previous medication. No 
cases or controls that experienced CADRs to anti-tuberculosis drugs had been 
previously treated for TB. In contrast seven of the 18 controls who had not experienced 
CADRs had been previously treated for different forms of TB. All the cases were 
admitted to hospital for management of their drug reactions compared to 11/30 (37%) of 
the controls. The reasons for the admission of the controls ranged from other diseases 
to CADR due to either TB and/or other medications. Thirteen of the fourteen cases 
(93%) had DRESS on initial presentation and a single case of SJS. Amongst the 
controls 7/12 (58%) had DRESS, the rest had SJS (1), SJS/TEN overlap (1), TEN (1), 
and pseudoporphyria (1), while one CADR was unknown. 
All cases and 12/30 (40%) controls (Group1a) were exposed to cover drugs during the 
process of re-challenge. Among those re-challenged, some had reaction to at least one 
of the cover drugs. The implicated drugs were moxifloxacin and ofloxacin among the 
cases and ethionamide, moxifloxacin and amikacin among the controls. 
Offending first-line drugs: 
Of the 14 cases that developed re-challenge reactions, 7 were due to RIF, 5 reacted to 
INH and 2 reacted to both RIF and INH independently. Only one control developed a re-
challenge reaction, attributed to PZA on oral re-challenge. Three of the RIF-associated 
re-challenge reactions were on patch testing and 5 were on oral re-challenge. All 4 
cases who developed INH-associated re-challenge reactions and the 2 who developed 
re-challenge reactions to both INH and RIF occurred on oral re-challenge. None of the 
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re-challenge reactions occurred following prick testing (Table S1). None of the re-
challenge reactions was life threatening. The skin changes resembled DRESS when 
present. Itch (10/14), erythema (1314) and rash (13/14) were the most frequent re-
challenge reactions amongst the 14 cases. Fever (8/14), hepatitis (6/14) oedema (5/14), 
sore eyes (2/14) and eosinophilia (2/14) occurred less frequently. 
HLA genotyping: 
HLA-B genotyping was successfully done in most of our participants (Table 2& 3). Due 
to technical problems, breaks in the cold chain during sample transportation and 
collection method used, most of the controls had poor quality and low DNA yields and 
thus limited PCR product for analysis. 
Cases compared to RIF and INH tolerant controls.  
There were no significant associations observed between HLA genotype and CADR 
when the cases were compared to the RIF and INH tolerant control population (Table3). 
Some genotypes did have an odds ratio that was greater than 1 when cases were 
compared to tolerant controls; however, this positive association was not statistically 
significant (Table 3). There were no HLA genotypes that showed a significant negative 
association i.e. a protective effect (Table 3). 
Cases compared to the general South African black population 
HLA-B*58:02 (OR=3.6; 95% CI: 1.4-8.99) and HLA-DRB1*09:01 (OR=15.3; 95% CI: 
2.1-113.1) showed significant positive associations with CADR when the cases were 
compared to the general South African black population (Table 3 and 4). A positive 
association (OR>1) that did not reach statistical significance emerged with other HLA 
genotypes when comparing the cases and the general South African black population 
(Table5 and 6). There were no HLA genotypes that showed a significant negative 





HLA-B genotype and the effect of HIV status 
Out of the 44 participants there were 36 who were HIV infected, 7 were HIV negative 
and the status of one was unknown. HLA-B *58.02 was found in 11  of the HIV infected 
cohort, it was found in 1 of the HIV negative cohort and for one HIV positive patient the 
HLA typing had failed and was not available. HLA-B *58.02 was not found to be 
statistically associated with HIV positive status (p=0.42). As there was no 
documentation of HIV status amongst the 200 general population historic controls the 
HIV association with HLA-B *58.02 could not be assessed. All study cases and controls 
had TB so this association with HLA-B *58.02 could not be computed. 
 
DISCUSSION 
To our knowledge, this is the first study to show an association between HLA-B*58:02 
and HLA-DRB1*09:01 alleles and severe cutaneous adverse drugs reactions secondary 
to rifampicin and isoniazid in an African population. We found HLA-B*58:02 and HLA-
DRB1*09:01 to be significantly more prevalent in patients who developed rifampicin and 
isoniazid-associated severe CADR as compared to a historic general South African 
black population. We found no significant associations between HLA genotype and 
rifampicin/isoniazid-associated severe CADR when we compared the cases to our study 
controls that had tolerated rifampicin and isoniazid. Considering the small sample size, 
the statistical significance for both alleles was associated with relatively tight confidence 
intervals. 
It has been convincingly shown that HLA genotype can serve as a predictor of CADR. 
The best-known example is the 100% association of HLA-B*15:02 in carbamazepine-
induced SJS/TEN in the Han Chinese populations. The same HLA-B*15:02 has been 
shown to have weaker associations in non-Asian populations (Ferrell & McLeod 2008). 
This association has led to a recommendation by the Food and Drug Administration 
(FDA) in the United States recommending that all patient of Asian descent should be 
screened for HLA-B*15:02 before initiating carbamazepine (Ferrell & McLeod 2008). 
This allele was not present in our patients or controls.  
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Other significant population and drug-specific HLA associations include HLA-B*58:01 in 
allopurinol-induced SJS/TEN in Han Chinese and Thai population (Tassaneeyakul et al. 
2009; Hung et al. 2005); dapsone-induced DRESS/DIHS and HLA-A*31:01 in Chinese 
population (Zhang et al. 2013); abacavir-induced hypersensitivity syndrome and HLA-
B*57:01 in western Australia (Mallal et al. 2002) and HLA-B*35:05 and nevirapine-
associated CADR in Thailand population (Chantarangsu et al. 2009). None of these 
HLA-B alleles were detected or strongly associated with CADR, if present, in our study. 
Specific HLA alleles have also been identified for other forms of ADR not involving the 
skin. None of these HLA alleles were detected with CADR in our study. These studies 
highlight that HLA-ADR associations are population, drug and ADR phenotype specific. 
Before the current study, to our knowledge, there was no data on HLA genotypes that 
are associated with CADR and anti-TB drugs in Africans. We identify 2 candidate HLA 
alleles that need confirmation of their association in African patients who develop 
rifampicin or isoniazid-associated CADR in larger studies. The value of identifying 
candidate alleles could lead to CADR preventative screening prior to initiating anti-
tuberculosis therapy in black South Africans. 
HLA-B*40:01 in Taiwan Han Chinese and HLA-B*07:02 in Caucasians have been found 
to be protective against CMZ-induced SJS/TEN (Hung et al. 2006; Alfirevic et al. 2006). 
Unfortunately we found no significantly protective HLA genotype for rifampicin/isoniazid-
associated CADRs in our study. 
We found that HLA-B*58:02 cases were more associated with clinical features 
suggestive of DRESS/DIHS.DRESS/DIHS was the prevalent phenotype of CADR, 
accounting for 93% of cases and only 53% of controls who experienced CADRs (Group 
1a). This association is worth exploring in more detail to determine CADR subtypes and 
their relationship to HLA genotypes in the black South African population. Interestingly 
most of the re-challenge reactions were suggestive of DRESS/DIHS. No firm conclusion 
could be drawn as the reactions were not allowed to develop and the patient treated as 
soon as an adverse effect was noted during the re-challenge. 
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Three of the cases developed re-challenge reactions to rifampicin patch test and 10 
were either due to oral rifampicin and/or isoniazid. Seven of our cases developed re-
challenge reactions to rifampicin, 5 reacted to isoniazid and two to both drugs. HLA-
B*58:02 was associated with both rifampicin and isoniazid-related cases. However, 
HLA-DRB1*09:01 was found in isoniazid related cases (one case due to INH and one 
case due to both rifampicin and isoniazid). We cannot draw a definitively conclusion that 
HLA-B*58:02 or HLA-DRB1*09:01 are specific to either isoniazid and/or rifampicin-
related CADR. Larger studies are needed to determine if HLA genotypes are TB-drug 
specific. 
HLA-B*58:02 is associated with rapid progression of HIV in a person who expresses the 
allele (Ngumbela et al. 2008). The HLA-B*58:02 noted in our cases and controls tolerant 
of the drugs might not be associated with CADR but could be a reflection of the HIV 
status and control in HIV-TB co-infected persons. Although our numbers were small 
there was no association between HIV infection and the presence of the HLA-B*58:02 in 
our study co-hort. HLA-B* 58:01 has been shown to be protective in HIV infected 
persons by reducing viral load replication and inducing cytotoxic T cell lymphocyte 
responses (Miura et al. 2009; O’Connell et al. 2009). Although present amongst the 
study and general population controls the numbers were too small to allow for 
meaningful analysis of a contribution of this effect on or results. A bigger study is 
needed to explore the association between HLA-B*58:02 and HLA-DRB1*09:01 in HIV-
TB co-infected persons with severe CADR and relate it to HIV disease progression. This 
would establish more firmly whether HIV is a confounder in the HLA-B*58:02 allele 
CADR association.  
The possible explanations for the large number of HIV infected individuals in our study 
population includes the high prevalence of HIV in the general South African population, 
higher rates of TB infection among HIV infected individuals and low social economic 
status (Department of Health Repulic of South Africa 2014). We also postulate 
theoretically the presence of HLA-B* 58:02 vs HLA-B*58:01 may play a role in the 




Study limitations are as follows:   
 The lack of a significant association between HLA genotype and CADR when 
cases were compared to our study controls could be explained by the small 
sample size. Alternatively other factors such as TB or viruses such as HIV or 
HHV6 present in both groups may be acting as confounders. 
 Our population was not homogenous comprising patients of black and mixed 
descend. 
 Due to the small study population and the rarity of the disease, we used only 
isoniazid and rifampicin associated CADR for HLA genotyping as they are the 
most important first line anti-tuberculosis drugs even though they are not the 
same calls of drug and do not share the same metabolism. A comparison of all 
first line anti-tuberculosis drugs for specific HLA associations in a larger study is 
needed. 
 Our preliminary hypothesis was that HLA may present the drug to T cells to 
induce hypersensitivity reactions, and therefore, we checked the HLA 
association. The sample size of cases was too small, and the p value became 
non-significant after correction for multiple testing. An increased sample size of 
cases as well as the drug-tolerant controls is necessary to investigate whether 
the corrected p value is still significant.  
 
In summary, HLA-B*58:02 and HLA-DRB1*09:01 may be associated with rifampicin 
and isoniazid-associated CADR .Alternately HLA-B*58:02 may be associated with 
HIV status rather than CADR. A sufficiently powered study is needed to confirm this 
association. 
 
MATERIALS AND METHODS  
Study participants 
A case-control study was conducted in, Cape Town, South Africa. The cases were 
patients with previous tuberculosis-associated severe CADR who were re-challenged 
with first-line anti-tuberculosis drugs and subsequently developed re-challenge 
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reactions to either isoniazid and/or rifampicin. Two groups of controls were selected. 
Control group 1 (30 patients), were patients that tolerated first line anti-tuberculosis 
drugs, either isoniazid and rifampicin tolerant during re-challenge following severe 
CADR (12 patients Group 1a) or isoniazid and rifampicin tolerant throughout a course of 
treatment (18 patients Group 1b). Control group 2 comprised 200 black South Africans 
from the general population whose HLA allele frequencies had previously been 
published (Paximadis et al. 2012). This study was conducted for one year (December 
2013-December 2014) but the cases and control group 1a were part of a larger study 
evaluating the best method for TB medication re-challenge/reintroduction after CADR. 
The Seventy four patients made up the cohort who were re-challenged prospectively 
over 8 years. The cases and controls which were recruited from this cohort to 
participate in our study according to protocol were 44. The remaining 30 who had all 
been re-challenged were not contactable or available for various reasons (9 dead, 5 
refused to participate, 16 not reachable). Of the 44 recruited, 14 were rifampicin re-
challenge positive cases, 7 were isoniazid re-challenge positive, 3 were pyrazinamide 
re-challenge positive, 2 were ethambutol re-challenge positive and 18 were full first line 
TB medication re-challenge negative controls. Some of the cases and controls recruited 
did not have blood samples taken for genotyping (5) while the rest (14) had failed 
genotyping. Finally genotyping data was available for 26 cases and control group 1a for 
analysis (Table S2 Figure 1). The control patients who experienced no ADRs to anti-
tuberculosis first-line were consecutive cases of patients on TB treatment admitted to 
hospital for unrelated reasons (Group 1b). Cases and controls were recruited in a ratio 
of 1:2 
Inclusion criteria of the study participants 
Cases:  
1. Participants willing and able to sign an informed consent  
2. Adults who had serious CADR and had positive oral provocation test, patch test or 
skin prick test to anti-tuberculosis drugs with either rifampicin and/or isoniazid identified 






1. Adult patients who had serious CADR but tolerated rifampicin and isoniazid after re-
challenge  
2. Adult patients who tolerated anti-tuberculosis drugs without developing any CADR 
 
Exclusion criteria  
1. Patients who are unwilling to sign an informed consent  
2. Patients who had serious CADR to multiple anti-TB drugs 
 
Management of participants before and during re-challenge 
Cases 
The anti-tuberculosis drugs were stopped when severe CADR to anti-TB drugs was 
suspected. Before re-challenge all patients were investigated to confirm active TB. 
Three second line anti-TB drugs (streptomycin, terizidone, ofloxacin, moxifloxacin, 
ethionamide, amikacin, kanamycin or para-amino-salicylic acid) to which the patient had 
not been previously exposed, were introduced to control active TB while waiting for the 
severe CADR and blood parameters to normalize. Depending on the sensitivities of the 
patient’s strain of TB, isoniazid followed by rifampicin, pyrazinamide and ethambutol 
were re-introduced consecutively and additively in accordance with a strict protocol. 
Once the patients had fully recovered the patients were re-challenged in hospital. A 
patch test was performed first, if negative, it was followed by a prick test and if this was 
also negative oral re-challenge was initiated. This re-challenge protocol was part of 
larger study which is still underway evaluating the best method to re-introduce 
medication after CADRs. For some cases only oral re-challenge was undertaken (Table 
S3) because of time constraints dictated by multiple co-morbidities and significantly ill 
patients. A positive re-challenge reaction following any of these re-challenge modalities 
lead to immediate withdrawal of the drug from the treatment regimen. Cases with a re-
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challenge reaction to either isoniazid and/or rifampicin following any of the three re-
challenges assessments constituted the cases (Figure 1). A re-challenge reaction was 
defined previously and fully described (Lehloenya et al. 2011). The patient 
demographics and CADR and re-challenge reactions are summarized in (Table S3 and 
S4). 
Controls  
Controls were consecutive patients who had tolerated rifampicin and isoniazid during 
the re-challenge process (12 patients, Group 1a) and consecutive patients who had 
been on TB treatment for at least 12 weeks without developing any ADR reaction but 
were admitted for unrelated medical problems (Group1b) (Figure 1). The causes of 
CADR in the control group 1a patients who had negative re-challenge to INH and Rif 
after CADR were due to drugs listed (Table S5). 
HLA genotyping 
Ten millilitres of a participant’s whole blood were collected in ethylenediaminetetraacetic 
acid (EDTA) tubes and stored at -80 degree Celsius within an hour of sample collection. 
Genomic DNA was isolated from the whole blood using the Gentra Puregene DNA 
purification kit (QIAGEN, Hilden, Germany). Each sample was typed for HLA-A, HLA-B, 
HLA-C, HLA-DRB1 alleles at high resolution by polymerase chain reaction with a Group 
Specific Sequencing Primers (GSSPs) typing method using the SeCore® HLA 
Sequence-Based Typing kits (Invitrogen by Life Technologies, Wisconsin, USA) 
according to the manufacturer’s protocols. Briefly, purified DNA was prepared to a 
working solution at 15-30 ng/μL in DNA hydration solution. For each amplification 
reaction, 50ng prepared DNA was combined 9.9 μl of Amp Mix with 0.1 μl of FastStart™ 
Taq DNA Polymerase. We confirmed the presence of PCR products (~1100 and 
~1300bp at A locus, or ~950 and ~1400bp at B locus, respectively) by 2% agarose gel 
electrophoresis. The resulting product was treated with 2μl ExoSAP-IT™ to degrade the 
unincorporated primers and hydrolyze the free nucleotides. For each positive PCR 
reaction, we set up forward and reverse sequencing reactions for exon 2, 3 and 4 at A, 
B, C or DRB loci. After cycle sequencing, an ethanol precipitation with PPT buffer was 
performed to remove excess terminators. The HLA type results were determined by 
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multicolor, fluorescence-based, BigDye® Terminator sequencing(Hung et al. 2010; 
Hung et al. 2005). 
 
Ethics 
The study was conducted in accordance with ethical principles contained in the Helsinki 
declaration. The study was approved by the Human Research Ethics Committee of the 
University of Cape Town (HREC REF: 582/2012) (Appendix 1). Informed written 
consent (Appendix 2) was translated into isiXhosa and Afrikaans, the other two major 
languages in the catchment area. Informed written consents were obtained from all 
study participants. Participant’s details were collected from their hospital medical 
records and recorded in a clinical record form (Appendix 3). Anonymity was assured by 
allocating consecutive numbers to patients and recruited control patients. 
Statistical analysis 
This is a pilot hypothesis generating study. As such the issue of multiplicity was 
deliberately not taken into account. Prior to this study, there was no available data to 
guide any sample power calculations. 
 
The data was analyzed using GraphPad Prism software. Comparisons of the 
frequencies of the HLA allele or carriers between the subgroups were performed using 
Fisher’s exact tests. As the pre-defined hypothesis based test was applied for the HLA 
association analysis, no correction of the p value for multiple testing was used in this 
study. Odds ratios (ORs) were calculated using Haldane’s modification, which added 
0.5 to all cells to accommodate possible zero counts. The statistical significance was 
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Table 1: Demographic and clinical characteristics of 14 cases that developed a re-
challenge reaction to rifampicin and/or isoniazid and 30 controls who tolerated rifampicin 
and/or isoniazid 
 






Age(years), median [IQR] 32 (28-37)  36 (33-39) 36(32-48) 36  (33-41) 
Gender: n (%)      
 Female  8 (57%) 6 (50%) 7 (39%) 13 (43%) 
 Male  6 (43%) 6(50%) 11 (61%) 17 (57%) 
Race:  n (%)     
 Black  10 (71%) 8 (67%) 13 (72%) 21 (70%) 
 Mixed race  4 (29%) 4 (33%) 5 (28%) 9 (30%) 
HIV status: n (%)     
 Positive  11 (79%) 12 (100%) 13 (72%) 25 (83%) 
 Negative  3 (21%) 0 (0%) 4 (22%) 4 (13%) 
 Unknown 0 (0%) 0 (0%) 1 (6%) 1 (4%) 
CD4 count cells/mm3, median [IQR] 149 (74-329) 108 (39-141) 300 (124-333) 141 (76-323) 
On ARVs 6 (43%) 5 (42%) 13 (72%) 18 (60%) 
PREVIOUS TB: n 0 (0%) 0 (0%) 7 (39%) 7 (23%) 
CADR to first-line TB treatment 14 (100%) 12 (100%) Na 12 (40%) 
Types of  initial CADR     
 SJS 1 (7%) 1 (8%) Na 1 (3%) 
 TEN 0 (0%) 1 (8%) Na 1 (3%) 
 SJS/TEN overlap 0 (0%) 1 (8%) Na 1 (3%) 
 DRESS/DIHS 13 (93%) 7 Na 1 (3%) 
 Pseudo porphyria 0 (0%) 1 (8%) Na 1 (3%) 
 Unknown 0 (0%) 1 (7%) Na 1(3%) 
CADR to second-line TB treatment 3 (21%) 1 (8%) Na Na 
 Moxifloxacin 2 0 Na Na 
 Ofloxacin 1 0 Na Na 
 moxifloxacin/ethionamide/amikacin 0 1 Na Na 
 
CADR = cutaneous adverse drug reaction; IQR = interquartile range; HIV = human immunodeficiency virus; TB =tuberculosis; ARVs= antiretroviral 
drugs; DRESS drug rash with eosinophilia and systemic symptoms; SJS = Stevens Johnson syndrome; TEN = toxic epidermal necrolysis; SJS/TEN = 















Table 2: The association between HLA- genotype and the HIV status 
 
 











































KS13 1 Case 58 *29:02 *66:01 *13:02 *58:02 *06:02 *06:02 *03:01 *08:04 
KS20 1 Case 329 *68:01 *68:02 *15:10 *82:02 *03:02 *03:04 *03:02 *10:01 
KS22 0 Case  *30:09 *68:02 *44:03 *58:02 *16:01 *18:01/02 *13:02 *15:03 
KS24 1 Case 320 *03:01 *30:02 FR FR *04:01 *06:02 *01:02 *03:02 
KS25 1 Case 80 *03:01 *30:01 *15:10 *58:02 *03:04 *06:02 *10:01 *15:03 
KS26 1 Case 223 *03:01 *23:01 *07:02 *58:02 *02:10 *06:02 *03:02 *13:01 
KS29 1 Case 457 *02:05 *30:02 *45:01 *58:01 *07:01 *16:01 *01:02 *13:01 
KS32 0 Case  FR FR *18:02 *44:02 FR FR *04:01 *12:02 
KS33 1 Case 145 *23:01 *30:04 *15:03 *58:02 FR FR *03:01 *08:04 
KS35 1 Case 63 *30:01 *33:01 *42:01 *42:01 *17:01 *17:01 *03:02 *03:02 
KS37 1 Case 401 *24:02 *30:01 *13:02 *18:01 *05:01 *06:02 *03:01 *07:01 
KS38 0 Case  *26:01 *32:01 *07:02 *27:05 *02:02 *02:10 *04:01 *09:01 
KS44 1 Case 74 FR FR *42:01 *58:02 FR FR *09:01 *13:01 
KS72 1 Case 149 FR FR *15:10 *58:01 FR FR *04:03 *14:01/54 
KS 7 1 control 1a 24 FR FR *18:01 *42:02 FR FR FR FR 
KS 8 1 contro1al 91 FR FR *42:01 *57:03 FR FR FR FR 
KS14 1 control 1a 22 FR FR *07:02 *58:02 FR FR FR FR 
KS16 1 control 1a 168 FR FR *57:03 *58:01 FR FR FR FR 
KS19 1 control 1a 39 FR FR *35:01 *53:01 FR FR FR FR 
KS21 1 control 1a Unk FR FR *08:01 *58:02 FR FR FR FR 
KS23 1 control 1a 395 FR FR *07:05 *13:02 FR FR FR FR 
KS45 1 control 1a Unk FR FR *15:01 *15:03 FR FR FR FR 
KS54 1 control 1a 44 FR FR *15:03 *27:05 FR FR FR FR 
KS57 1 control 1a 131 FR FR *15:01 *47:01 FR FR FR FR 
KS58 1 control 1a 125 FR FR *18:01 *44:03 FR FR FR FR 
KS66 1 control 1a 141 FR FR *57:02 *58:02 FR FR FR FR 
KS 1 0 control 1b  FR FR *07:02 *15:03 FR FR FR FR 
KS 2 1 control 1b 5 FR FR *39:10 *42:01 FR FR FR FR 
KS 9 1 control1b 314 FR FR *15:10 *42:01 FR FR FR FR 
KS10 1 control 1b 323 FR FR *58:02 *58:02 FR FR FR FR 
KS12 1 control 1b 101 FR FR *08:01 *13:02 FR FR FR FR 
KS17 1 control1b 236 FR FR *42:01 *44:03 FR FR FR FR 
KS18 1 control 1b 333 FR FR *42:02 *58:02 FR FR FR FR 
KS30 1 control 1b 124 FR FR *15:10 *42:01 FR FR FR FR 
KS31 0 control 1b  FR FR *15:10 *42:01 FR FR FR FR 
KS34 1 control 1b 76 FR FR *44:03 *58:02 FR FR FR FR 
KS36 unk control 1b  FR FR *13:02 *58:02 FR FR FR FR 
KS39 1 control 1b 274 FR FR *42:01 *58:01 FR FR FR FR 
KS42 1 control 1b 720 FR FR *13:02 *15:03 FR FR FR FR 
KS43 0 control 1b  FR FR *15:10 *44:03 FR FR FR FR 
KS53 1 control 1b 548 FR FR *42:01 *58:02 FR FR FR FR 
KS55 0 control 1b  FR FR *45:01 *58:02 FR FR FR FR 
KS56 1 control 1b 300 FR FR *15:03 *27:05 FR FR FR FR 
KS74 1 control 1b 724 FR FR *07:02 *08:01 FR FR FR FR 
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Table 3: Comparison of the HLA-B allele frequencies among the cases that developed a 
re-challenge reaction to rifampicin and/or isoniazid and the two control groups  
 
 Cases n=13 Tuberculosis controls n=30 Population controls = 200 
HLA n  n  OR (95% CI) p value n OR (95% CI) p value 
          
B*07:02 2 3 1.6(0.2 - 10.1) 0.636 18 1.7(0.4 - 7.87) 0.349 
B*07:05 0 1 0.1(0 - 860.4) 1  na  na na 
B*08:01 0 3 0(0 - 250.2) 0.55  na na na 
B*13:02 2 4 1.2(0.2 - 6.8) 1 8 4.1(0.8 - 20.29) 0.119 
B*15:01 0 2 0.1(0 - 392) 1  na na na 
B*15:03 1 5 0.4(0 - 4) 0.663 34 0.4(0.1 - 3.32) 0.711 
B*15:10 3 4 1.8(0.4 - 8.8) 0.427 32 1.5(0.4 - 5.34) 0.462 
B*18:01 1 2 1.2(0.1 - 13.4) 1 12 1.3(0.2 - 9.98) 0.564 
B*18:02 1 0 50.3(0 - 401350) 0.302 0 320(0 - 2569260.31) 0.061 
B*27:05 1 2 1.2(0.1 - 13.4) 1 0 320(0 - 2569260.31) 0.061 
B*35:01 0 1 0.1(0 - 860.4) 1  na na na 
B*39:10 0 1 0.1(0 - 860.4) 1  na na na 
B*42:01 3 8 0.8(0.2 - 3.5) 1 36 1.3(0.4 - 4.67) 0.721 
B*42:02 0 2 0.1(0 - 392) 1 0 320(0 - 2569260.31) 0.061 
B*44:02 1 0 50.3(0 - 401350) 0.302  na na na 
B*44:03 1 4 0.6(0.1 - 5.3) 1 23 0.6(0.1 - 5.01) 1 
B*45:01 1 1 2.4(0.1 - 39.1) 0.516 26 0.6(0.1 - 4.49) 1 
B*47:01 0 1 0.1(0 - 860.4) 1  na na na 
B*53:01 0 1 0.1(0 - 860.4) 1  na na na 
B*57:02 0 1 0.1(0 - 860.4) 1  na na na 
B*57:03 0 2 0.1(0 - 392) 1  na na na 
B*58:01 2 2 0.1(0 - 392) 0.581 32 0.9(0.2 - 4.18) 1 
B*58:02 7 10 1.8(0.6 - 5.5) 0.376 38 3.6(1.4 - 8.99) 0.013 
13 cases out of 14 cases had successful HLA-B genotyping and 1 failed. 
Controls are: 30 patients that tolerated rifampicin and/or isoniazid) and 200 black South African from the general population. 

















Table 4: Comparison of the HLA-DRB1 allele frequencies among the cases that 
developed a re-challenge reaction to rifampicin and/or isoniazid and black South African 
from the general population 
 
 Cases n=14  Population controls= 200 
HLA N n OR (95% CI) p value 
DRB1*01:02 2 19  1.6(0.3-7.07)  
 
0.639  
DRB1*03:01 3 30  1.5(0.4 -5.11) 0.466  
DRB1*03:02 5 39  2.0 (0.7-5.62) 0.191  
DRB1*04:01 2 10  2.9 (0.6-13.78) 0.182  
DRB1*04:03 1 0  43.7(1.7-1097.78) 0.065  
DRB1*07:01 1 28  0.5 (0.1-3.7) 0.710  
DRB1*08:04 2 17  1.8 (0.4 -8.0) 0.357  
DRB1*09:01 2 2  15.3(2.1-113.1) 0.023  
DRB1*10:01 2 10  2.9(0.6 -13.8) 0.182  
DRB1*12:02 1 0  43.7(1.7-1097.8) 0.065  
DRB1*13:01 3 50  0.8(0.2-2.9) 1.000  
DRB1*13:02 1 23  0.6(0.1-4.6) 1.000  
DRB1*14:01 1 3  4.6(0.5-44.9) 0.238  
















Table 5: Comparison of the HLA-C allele frequencies among the cases that developed a 
re-challenge reaction to rifampicin and/or isoniazid and black South African from the 
general population 
 
 Cases n=10  Population controls= 200 
HLA n  n  OR (95% CI) p value 
C*02:02 1 36 0.5(0.1-4.0)  
 
1.000  
C*02:10 2 0 888.8(0.1-6431264.5) 0.002  
C*03:02 1 6 3.5(0.4-30.2) 0.291  
C*03:04 2 20 2.1(0.4-9.5) 0.282  
C*04:01 1 48 0.4(0.1-3.0) 0.492  
C*05:01 1 3 6.5(0.7-64.6) 0.178  
C*06:02 5 60 1.9(0.7-5.4) 0.214  
C*07:01 1 30 0.6(0.1-4.9) 1.000  
C*16:01 2 26 1.6(0.3-7.1) 0.635  
C*17:01 2 44 0.9(0.2-4.0) 1.000  

















Table 6: Comparison of the HLA-A allele frequencies among the cases that developed a 
re-challenge reaction to rifampicin and/or isoniazid and black South African from the 
general population 
 
 Cases n=11  Population controls= 200 
HLA n  n  OR (95% CI) p value 
A*02:05 3 27 2.2(0.6-7.8)  0.199  
A*03:01 1 26 0.7(0.1-5.3) 1.000  
A*23:01 2 32 1.2(0.3-5.1) 0.694  
A*24:02 1 8 2.3(0.3-19.5) 0.385  
A*26:01 1 3 5.9(0.6-58.2) 0.193  
A*29:02 1 25 0.7(0.1-5.5) 1.000  
A*30:01 3 40 1.4(0.4-5.0) 0.481  
A*30:02 2 38 0.9(0.2-4.2) 1.000  
A*30:04 1 7 2.6(0.3-22.0) 0.351  
A*30:09 1 0 380.9(0.0-3063625.4) 0.052  
A*32:01 1 5 3.6(0.4-32.1) 0.276  
A*33:01 1 1 15.8(1.1-233.1) 0.102  
A*66:01 1 3 5.9(0.6-58.2) 0.193  
A*68:01 1 13 1.4(0.2-11.2) 0.533  
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74patients with TB and severe TB-associated CADR 







Table S1: Association between CADR and modalities of re-challenge among the of 14 
cases that developed a re-challenge reaction to rifampicin and/or isoniazid  
Mode of re-challenge Number  
 RIF patch testing reaction 3 
 INH oral re-challenge reaction 4 
 RIF oral re-challenge reaction 5 
 INH & RIF oral re-challenge reaction 2 
INH= isoniazid and RIF= rifampicin 












































Table S2: The distribution of the cases, controls and HLA genotyping 
 
Potential positive 
cases for inclusion 








*RIFAMPICIN 14 14 8 6 5 failed genotyping 
1 blood not sent 
*ISONIAZID 7 7 6 1 1 failed genotyping 
PYRAZINAMIDE 3 3 1 2 2 failed genotyping 
ETHAMBUTOL 2 2 0 2 2 failed genotyping 
SUCCEFUL RHZE 
RECHALLENGE 
18 18 11 7 3 blood not sent 
4 failed genotyping 
TOTAL 44 44 26 18 18 
2 cases positive to rifampicin re-challenge were also positive on isoniazid re-challenge. 




































PT=patch test; SPT skin prick test; oral= oral re-challenge; Yes=PT/SPT/oral re-challenge was done and there was a reaction; No= PT/SPT/oral re-
challenge was done but there was no a reaction; ND = PT/SPT/oral re-challenge was not done at all; CADR=cutaneous adverse drug reaction; 
DRESS=Drug reaction with eosinophilia and systemic symptoms; RIF=rifampicin, INH=isoniazid, PZA=pyrazinamide; moxiflox=moxifloxacin, 






 CADR 2nd line 
TB meds 
Method  used to  induce re-challenge reaction  and 
outcome 
RE-challenge reaction features 






erythema rash swelling rigors abdominal 
pain 
Diarrhoea fever hepatitis eos CADR  culprit 
TB drug 
KS7 0 No No No 0                  
KS8 0 No No No 0                  
KS13 0 ND ND Yes 1 0 0 1 0 0 0 1 1 0 0 0 0 0 0 1 DRESS RIF 
KS14 0 No No No 0                  
KS16 0 ND ND No 0                  
KS19 0 ND ND No 0                  
KS20 0 Yes ND ND 1 0 0 1 0 0 1 1 1 1 0 0 0 1 1 0 DRESS RIF 
KS21 0    0                  
KS22 0 Yes ND ND 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 DRESS RIF 
KS23 0 No No No 0                  
KS24 0 ND ND Yes 1 0 0 1 0 0 0 1 1 0 0 0 0 0 1 0 DRESS RIF 
KS25 0 ND ND Yes 1 0 0 1 0 0 0 1 1 1 0 0 0 1 0 0 DRESS RIF 
KS26 0 Yes ND ND 1 0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 DRESS RIF 
KS29 1 (moxiflox) ND ND Yes 1 0 0 1 0 0 1 1 1 1 0 0 0 1 0 0 DRESS RIF 
KS32 0 No No Yes 1 0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 DRESS INH 
KS33 1 (oflox) No No Yes 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 DRESS INH 
KS35 0 ND ND Yes 1 0 0 1 0 0 0 1 1 0 0 0 0 1 1 0 DRESS RIF&IN
H 
KS37 1 (moxiflox) ND ND Yes 1 0 0 1 0 0 0 1 1 0 0 0 0 1 1 0 DRESS RIF 
KS38 0 ND ND Yes 1 0 0 1 0 0 0 1 1 0 0 0 0 0 1 0 DRESS INH 
KS44 0 ND ND Yes 1 0 0 0 0 0 0 1 1 1 0 1 1 1 1 0 DRESS RIF&IN
H 
KS45 0 ND ND ND 0                  
KS54 0 ND ND No 0                  
KS57 1 (moxiflox, 
ethion, ami) 
ND ND No 0                  
KS58 0 ND ND No 0                  
KS66 0 ND ND Yes 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 DRESS PZA 
KS72 0 0 0 Yes 1 0 0 0 0 0 0 1 1 1 1 0 0 1 1 0 DRESS INH 
Total 4 3 9 12 15  1 1 10 0 0 2 13 13 5 1 1 1 8 7 2 15 15 
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Table S4: Blood parameters on admission CADR 











5-40U/l 5-40U/l 5-40U/l 5-40U/l 0-21µmol/l 0-6µmol/l 2.6-7.0mmol/l 64-104µmol/l  
KS7 4.29 0.97 0.97 0.34 12 13 48 90 3 1 8.6 208 DRESS 
KS8 6.22 0.03 0.08 0.49 38 38 37 41 3 1 3.2 54 DRESS 
KS13 5.66 0.5 0.5 0.5 19 29 29 30 2 1 6.9 102 DRESS 
KS14 3.88 0.1 0.17 0.67 26 33 53 126 6 3 7.3 66 SJS 
KS16 unk unk unk unk unk unk unk unk unk Unk unk unk DRESS 
KS19 4.9 0.11 0.11 0.4 22 24 36 36 2 3 3.3 66 TEN 
KS20 6.52 0.05 0.05 0.65 179 179 79 79 19 11 3.7 78 DRESS 
KS21 unk unk unk unk unk unk unk unk unk Unk unk unk unk 
KS22 4.58 0.9 0.9 0.94 27 27 41 41 5 2 1.1 66 DRESS 
KS23 3.53 0.14 0.25 ND 52 52 31 31 4 ND 3.8 57 DRESS 
KS24 11.1 0.05 0.05 0.25 132 132 187 187 4 1 8.7 73 DRESS 
KS25 8.14 0.01 0.01 ND 58 329 106 821 8 2 3.5 71 DRESS 
KS26 8.07 0.08 0.08 0.67 53 53 32 57 4 ND 5.5 34 DRESS 
KS29 5.99 0.2 0.2 2.48 54 54 80 80 4 1 2.2 54 DRESS 
KS32 4.71 0.16 0.25 1.77 19 19 30 46 5 1 5.2 85 DRESS 
KS33 7.16 0.04 0.22 ND 168 168 118 118 6 2 2.7 40 DRESS 
KS35 4.94 0.72 1.88 0.43 40 653 49 727 11 8 3.7 67 DRESS 
KS37 5.39 0.15 0.35 1.02 52 140 47 148 4 3 2 42 DRESS 
KS38 8.49 0.43 0.43 0.77 63 219 100 288 18 10 6.1 46 DRESS 
KS44 1.52 0.07 0.07 0.29 19 31 31 32 3 2 4.2 69 DRESS 
KS45 ND ND ND ND ND ND ND ND ND ND ND ND DRESS 
KS54 3.05 0.06 0.22 ND 13 33 35 83 16 15 3.8 35 PSEUDOPORPHYRIA 
KS57 3.74 0.65 0.65 0.84 51 91 89 169 5 3 9 131 DRESS 
KS58 10.53 0.12 0.59 5.08 9 9 7 21 27 ND 3.7 93 DRESS 
KS66 2.85 0.18 0.27 ND 25 47 57 59 ND ND ND ND SJS/TEN overlap 
KS72 4.43 0.12 0.22 1.18 16 16 38 41 5 2 2.6 75 SJS 
WCC=white cell count; Eos= eosinophils; Lymphs= lymphocytes; AST=aspartate transaminase; ALT=alanine transaminase; Tot bili=total bilirubin; Conj 











Table S5: The causes of CADR in the control group 1a patients who had negative re-
challenge to INH and Rif after CADR 
SORT # BACTRIM ARVS ANTI TB 





7 1# 0 0 0 0 0 
8 1# 0 0 0 0 0 
14 1# 0 0 0 0 0 
16 0 1+ 0 0 0 0 
19 1# 1+ 0 0 0 Phenytoin 
21 0 1+ 0 0 0 0 
23 0 1+ 0 0 0 vit B complex 
45 0 1+ 0 0 0 0 
54 1# 0 0 0 0 0 




58 0 0 0 0 0 0 
66 0 0 PZA* 0 0 0 
*Positive re-challenge 
#Bactrim withdrawn – not re-challenged 
+ARVs changed to exclude nevirapine and effavarence 
















                                                                    
 
 



































Appendix 2a: English consent form 
72 
 
GENOMICS STUDY OF ANTI-TUBERCULOSIS DRUG-INDUCED 
HYPERSENSITIVITY REACTIONS 
I,                                  agree to take part in this research on my own free will. The reasons, benefits and the risks of the research 
have been explained to me in the language I understand by Doctor.                                          
I have been told that the reason for this research is to find out which of my genes contributed to the reaction I had to my treatment 
for tuberculosis. 
Two blood samples of 5ml each will be collected from me. One will be sent to a laboratory overseas that has the ability to do the 
tests and the other sample will be stored here in Cape Town for future studies related only to this research. The samples sent 
overseas will be destroyed immediately after the experiments. My expressed permission will be obtained for these future studies. I 
understand that the research may not benefit me directly, but may help others in the future including my own children or family.   
The records of the research will be kept safely and only the team doing the research will be able to use it. The findings of the study 
may be published in scientific journals and meetings, but I will not be identified. I understand that I will not get any payment for the 
work related to the research. 
Would you like to know the finding of the research                yes _                       no _          
If yes at the following address and telephone number: ____________________   .                               
 
If you have any further questions you can contact Dr Shebe or Dr Lehloenya at 021 404 5269                                                 
Permission of this research was given on         29th May, 2013                                 by the Human Research Ethics Committee of the 
University of Cape Town. If you have any complaints about the conduct of this research please contact Professor Marc Blockman on 
Tel: 0214066492 
I agree to take part of my own free will and I can stop at any time without having to give a reason for it. 
__________________________                     _____________________________ 
Printed name of participant                             Signature, Mark, or Thumb Print  
__________________________           ______________________________ 
Investigator’s name (Print)                             Signature 
Date ____________________                             
____________________                                     ____________________                      
Witness’s name (Print)               Signature 






CONSENT TO OBTAIN A SPECIMEN FOR GENETIC TESTING 
SAMPLE TYPE: BLOOD 
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GENETIC TESTING REQUESTED FOR: 
Susceptibility to adverse reactions to TB drugs 
The intended purpose of this test is predictive 
1. I have been informed about the purpose of this genetic test. 
2. I have received an explanation of the limitations of this genetic test. 
2. Dr____________________ has discusses the benefits and risks of this genetic test with me. 
4. I understand some genetic tests can involve possible medical, psychological or insurance issues of my 
family 
5. I have been informed how I will receive the results 
6. I have been informed who may have access to my blood sample, and that any leftover sample may be 
retained by researchers at the University of Cape Town. 
7. I have been informed who may have access to my genetic test results, which is part of my confidential 
medical records. 
8. My questions have been answered to my satisfaction. 
Permission of this research was given on                   29th May, 2013                       by the Human 
Research Ethics Committee of the University of Cape Town. If you have any complaints about the 
conduct of this research please contact Professor Marc Blocman on Tel: 0214066492 
I consent to have samples taken from genetic testing for the condition listed above and I am aware that I 
can withdraw this consent at any time without having to give a reason for it 
________________________________           _____________________________ 
Printed name of participant                        Signature, Mark, or Thumb Print  
________________________________           ______________________________ 
Investigator’s name (Print)                         Signature 
Date ____________________                             
____________________                                     ____________________________                         






 Appendix 2b: IsiXhosa consent form 
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GENOMICS STUDY OF ANTI-TUBERCULOSIS DRUG-INDUCED 
HYPERSENSITIVITY REACTIONS 
(Iincukacha ngegenes ezichaphazelekayo ekulweni komzimba namachiza esifo semiphunga)  
Mna ………………………………………………. Ndiyavuma ukuthata inxaxheba kolu phando ngaphandle kokugunyaziswa. Injogo, 
inzuzo kunye namakhwiniba zichaziwe nguGqirha……………………………….. esebenzisa ulwimi olucacileyo. 
Ndixelelwe ukuba iinjongo zoluphando kukuzama ukufumana ukuba iigenes zam ziyachaphazeleka kusini na ekulweni komzimba 
wam namachiza esifo semiphunga. 
Kuya kuthathwa kum igazi elilinganiselwa kwisihlanu samamililitha (tisipuni) kabini kuphela. Elinye igazi liyakuthunyelwa kumaziko 
okuhlola igazi akumazwe angaphesheyeya kolwandle, ukuze lihlolwe khona. Elinye igazi liyakugcinwa kumaziko okuhlola igazi 
alapha eKapa ukuze lihlolwe kwixesha elizayo lihlolwelwa kwaolu phando kuphela. Igazi elithunyelwe kumazwe angaphesheya liya 
kulahlwa kwangoko kwakuqgitywa uhlolo. Imvume yam iyakuphinde icelwe xa kufuneka olunye uhlolo kwixesha elizayo. Ndiyazi 
ukuba kungenzeka mna ngokwam ndingazuzi nto kolu phando koko kuzuze abanye abantu ekuquka kubo abantwana nosapho 
lwam. 
Amacwecwe oluphando ayakugcinwa eluvalelweni ukuze afumaneke kuphela kubantu abenza olu phando kuphela. Iziphumo 
zophando kungenzeka zipapashwe emaphepheni enzululwazi kunye nasezintlanganisweni kodwa igama lam alisayi 
kungqanyaniswa nezo ziphuma. Ndiyazi andisayi kuhlawula ngokuthatha inxaxheba kolu phando. 
Ungathanda na ukuzazi iziphumo zophando? Ewe     noba    hayi  
Ukuba uthi ewe nceda ubhale idilesi nenombolo yakho 
yemfonomfono………………………………………………………………………………………………………………………………………
………………………………………… 
Ukuba unemibuzo ngophando tsalela umnxeba uGqirha Shebe okanye uGqirha Lehloenya ku 021 404 5269. 
Imvume yokwenza uphando ifumaneke ngomhla ka………………………inikezwa licandelo leHuman Research ethics committee kwi 
Univesiti yaseKapa (University of Cape town). Ukuba zikhona izikhalazo mayela nolu phando nceda utsalele umnxeba uProfesa 
Marc Blockman ku 021 406 6492.Ndivumile ukuthabatha inxaxheba kolu phando kwaye ndiyazi ndingasirhoxisa esi sivumelwano 
nangaliphi ixesha ngaphandle kokunika izizathu. 
Igama lophandwayo                                      utyikityo, uphawu okanye umnwe 
……………………………………..                      ............................................................ 
Igama lomphandi                                            utyikityo 
………………………………….                         ………………………………………… 
Umhla……………………………. 
Igama lengqina                                               utyikityo 





IMVUME YOKUNIKEZELA NGEGAZI KUHLOLO LWEGENES 
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Uhlobo lwesample: Igazi 
Uhlobo lohlolo   lwegenes elizakwenziwa:  
Kungaba zikhona na izintsolo zokuthi umzimba wam ungahle ulwe namachiza esifo semiphunga. 
1. Ndixelelwe ngeenjongo zolu hlolo lwegenes 
2. Ndichazelwe ngamakhwiniba anxulumene nolu hlolo lwegenes 
3. UGqhirha…………………………….undichazele ngendzuzo nokungahle kungahabi kakuhle kolu hlolo lwegenes. 
4. Niyazi ukuba ukuhlolwa kwe genes zam kungahle kudale ingxaki emzimbeni, egqondeni nomshwalense (insurance) kusapho 
lwam. 
5. Ndichazelwe ukuba ziyakufumaneka njani iziphumo zophando 
6. Ndichazelwe ukuba ngubani oyakukwazi ukufumana igazi endinikezele ngalo, nokuba igazi eliseleyo liyakugcinwa ngabaphandi 
kwiUnivesiti yase Kapa (Unuversity of cape Town) 
7. Ndichazelwe ukuba ngubani oyakufumana iziphumo zophando eziyingxenye zeemfihlo eziqulathwe kwingcombolo zonyango. 
8. Imibuzo yam iphendulwe ngokwanelisayo 
Imvume yokwenza uphando ifumaneke ngomhla ka………………………inikezwa licandelo leHuman Research ethics committee kwi 
Univesiti yaseKapa (University of Cape town) Ukuba zikhona izikhalazo mayela nolu phando nceda utsalele umnxeba uProfesa 
Marc Blockman ku 021 406 6492 
Ndivumile ukuba kuthathwe igazi kuhlolo lwegenes phantsi kwezi meko zingenthla kwaye ndiyazi ndingasirhoxisa esi sivumelwano 
nangaliphi ixesha ngaphandle kokunika izizathu. 
Igama lophandwayo                                      utyikityo, uphawu okanye umnwe 
……………………………………..                      ............................................................ 
Igama lomphandi                                            utyikityo 
………………………………….                         ………………………………………… 
Umhla……………………………. 
Igama lengqina                                               utyikityo 













GENOMIKA VAN ANTI-TUBERKULOSE MIDDEL GEINDUSEERDE 
HIPERSENSITIWITEITS REAKSIES 
Ek, ____________ stem in om deel te neem aan hierdie navorsing uit vrye wil. Die redes, voordele en risikos hieraan verbonde is 
aan my meegedeel deur dokter _______ in n taal wat ek verstaan. 
Ek is meegedeel dat die rede vir hierdie navorsing is om te bepaal of my gene bygedra het tot die reaskie wat ek agv my anti-TB 
medikasie gehad het. 
Twee bloed monsters van 5ml elk sal van my geneem word. Een sal na n laboratorium in die buiteland gestuur word wat oor die 
nodige toetse beskik en die ander monster sal in Kaapstad geberg word vir moontlike verdere toetse wat slegs met hierdie 
navorsing verband sal hou. Eersgenoemde monster sal vernietig word sodra die toetse afgehandel is. My toestemming sal verkry 
word alvorens verdere toetse op die ander monster verrig word. Ek verstaan dat die navorsing my nie direk sal bevoordeel nie, maar 
dat dit vir andere tot voordeel mag wees in die toekoms, insluitende my kinders en familie. 
 
Die rekords van die navorsing sal veilig bewaar word en slegs die persone wie die navorsing gedoen het sal toegang daartoe he. 
Die resultate van die navorsing mag gepubliseer word in wetenskaplike joernale en by wetenskaplike vergaderings voorgedra word, 
maar ek sal nie geidentifiseer word nie. Ek verstaan dat ek nie vir die werk verbonde aan die navorsing betaal sal word nie.  
 
Wil u ingelig word aangaande die bevindinge van die navorsing?    Ja   nee 
 
Indien wel, wat is u adres en telefoon nommer? ______________________________ 
 
Indien u enige verdere vrae het kan u drs Shebe of Lehloenya kontak by 021 404 5269 
 
Toestemming vir hierdie navorsing is gegee op __________ deur die Menslike Navorsings Etiese Komitee van Kaapstad. Indien u 
enige klagtes aangaande die uitvoering van die navorsing het kontak asb Prof Marc Blockman by 021 406 6492.  
 
Ek stem in om deel te neem uit vrye wil en kan ter enige tyd onttrek sonder om n rede daarvoor te verskaf.  
_________________________                              _____________________________ 
Geskrewe naam van deelnemer:                             Handtekening of duim vingerafdruk 
 
_______________________                                  _____________________________ 
Ondersoeker se naam (skryf)                                  Handtekening 
 
 
Datum__________________                                 Datum_______________________ 
 
__________________                                           _____________________________ 
























TOESTEMMING VIR DIE VERKRYGING VAN N MONSTER VIR GENETIESE 
TOETSE 
 
MONSTER TIPE: BLOED 
 
GENETIESE TOETS AANGEVRA VIR: 
 
Vatbaarheid vir newe effekte van TB medikasie 
Die veronderstelde doelstelling van die toets is voorspellend. 
 
1. Ek is ingelig aangaande die doelstelling van die genetiese toets. 
2. Aan my is die tekortkominge van die toets verduidelik 
3. Dr. _____ het met my die voordele en risikos van die genetiese toets bespreek. 
4. Ek verstaan dat party genetiese toetse moontlike mediese, psigologiese of versekerings 
implikasies vir my en my familie kan inhou. 
5. Aan my is meegedeel hoe ek die resultate kan bekom. 
6. Aan my is meegedeel wie toegang tot my bloed monster het en dat wat daarvan oor is deur die 
navorsers van die Universiteit van Kaapstad gehou kan word . 
7. Aan my is meegedeel wie toegang het tot my genetiese toets resultaat en dat dit deel uitmaak 
van my konfidesiele mediese rekort. 
8. My vrae is beantwoord na my bevrediging. 
 
Toestemming vir die navorsing was gegee op ____________ deur die Menslike Navorsings 
Etiese Kommittee van die Universiteit van Kaapstad. Indien ek enige klagtes aangaande die 
uitvoering van die navorsing het kan ek Prof Marc Blockman kontak by 021 404 6492. 
Ek gee toestemming dat monsters van my geneem mag word vir genetiese toetse vir die 
toestand vermeld hierbo en ek is bewus dat ek hierdie toestemming ter enige tyd kan onttrek 
sonder om n rede daarvoor te verskaf. 
 
 
_________________________                              _____________________________ 
Geskrewe naam van deelnemer:                             Handtekening of duim vingerafdruk 
 
_______________________                                  _____________________________ 
Ondersoeker se naam (skryf)                                  Handtekening 
 
 
Datum__________________                                 Datum_______________________ 
 
__________________                                           _____________________________ 







Appendix 3: Clinical research form 
A. Patient Demographics 
A1: Surname: ________________________________A2: Name _____________________________  
A3: Folder No: ______________________________ A4: Date of birth: _____________________ 
A5: Sex:  Male (1) Female (2) 
A6: Ethnicity:  Asian Yes (1) No (0)   Black Yes (1) No (0)   
       Coloured Yes (1) No (0)   Indian Yes (1) No (0) White Yes (1) No (0)  
       Other capture text______________________________     
B: Comorbidities: 
             Hypertension Yes (1) No (0) Diabetic (Yes) No (0) Epilepsy (Yes) No (0)   
             Others capture text ________________________________________________ 
C: HIV status:    
              C1: HIV status known Yes (1) No (0)   
C2: HIV infected Yes (1) No (0)     
C3: CD4 count known: Yes (1)      No (0) 
C4: If known value of CD4 count: ____________cells/mm3 
C5: On HAART Yes (1) No (0) 
D: Previous TB history 
                 D1: Yes (1)         No (0) 
                  D2: Date of diagnosis_______________________________________________ 
                  D3: How was the TB diagnosed Sputum Yes (1) No (0)   CXR Yes (1) No (0)  
                        Abd USS Yes (1) No (0)   FNAB Yes (1) No (0) CSF Yes (1) No (0)  
                       Other capture text   _________________________________________   
                 D4:   Sensitivity testing Yes (1) No (0)    
                 D5: If Yes, Was it MDR Yes (1) No (0) Monoresistance Yes (1)   No (0)  
                        Nonresistance Yes (1) No (0)         
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E:  Previous completion Tb treatment 
                 E1: Yes (1)         No (0)     
                 E2:  If yes, how long was the TB treatment _________________________?   
                 E3: If No, how long was the TB treatment _________________________? 
 F: ADR in previous TB treatment?  Yes (1) No (0)                  
                 F1: Specify type of drug reaction 
  Stevens Johnson syndrome (SJS)    Yes (1) No (0) Toxic epidermal necrolysis (TEN)           
  Yes (1) No (0) SJS/TEN overlap        Yes (1) No (0)        
 Drug hypersensitivity syndrome (DHS)/ drug reaction with eosinophilia and  
  systemic symptoms (DRESS) Yes (1) No (0)   
  Lichenoid drug reaction       Yes (1) No (0)    Photo induced drug reaction      Yes (1)  
  No (0)     Fixed drug eruption Yes (1) No (0)   
 Vasculitis         Yes (1) No (0)            AGEP       Yes (1) No (0)         Angioedema        Yes  
 (1) No (0)      Morbilliform/exanthematous Yes (1) No (0)   




G: Previous causative TB drugs known:    
G1: Yes (1)            No (0)          
             G2: If yes specify drug(s): 
                    Rifampicin Yes (1) No (0) Isoniazid   Yes (1) No (0)   Pyrazinamide Yes (1) No  
                     (0)     Ethambutol Yes (1) No (0)     streptomycin Yes (1) No (0)               
                    Ethionamide Yes (1) No (0)      Ofloxacin Yes (1) No (0)     Ciprofloxacin Yes (1)       
                    No   (0)     Azithromycin Yes (1) No (0)       Amikacin Yes (1) No (0)         
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                    Thiacetazone Yes (1) No (0)      Clofazimine Yes (1) No (0)         Clarithromycin  
                    Yes (1) No (0)    kanamycin Yes (1) No (0)    Terizidone Yes (1) No (0)   PAS Yes  
                    (1) No (0)     Cycloserine Yes (1) No (0)            Rifabutin Yes (1) No (0)      
                    Other (capture text) ___________________________________ 
 
 
H: Previous re-challenge of the TB medication: 
              Yes (1)     No (0) 
              H1: If Yes, Date of Re-challenge ______________________________  
              H2: Date of completion of re-challenge ______________________ 
H3: If No, Reasons capture text________________________________________________ 
 
I: Outcome of previous re- challenge  
             I1: Successful re-challenge with the patient on at least 4 anti Tb drugs  
       Yes (1)       No (0) 
             I2: If yes, specify anti Tb drugs 
                    Rifampicin Yes (1) No (0)    Isoniazid Yes (1) No (0)    Pyrazinamide Yes (1) No  
                    (0)    Ethambutol Yes (1) No (0)     streptomycin Yes (1) No (0)     
                    Ethionamide Yes (1) No (0)    Ofloxacin Yes (1) No (0)     Ciprofloxacin Yes (1) No  
                    (0)     azithromycin Yes (1) No (0)       amikacin Yes (1) No (0)         
                    Thiacetazone Yes (1) No (0)      Clofazimine Yes (1) No (0)         Clarithromycin  
                    Yes (1) No (0)    kanamycin Yes (1) No (0)  Terizidone Yes (1) No (0)    PAS Yes  
                   (1) No (0)     Cycloserine Yes (1) No (0)     rifabutin Yes (1) No (0)     
                Other (capture text) ___________________________________ 
             I3: Date of discharge_____________________________________________________. 
              I4: Completed treatment Yes (1) No (0)   
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              I5: If yes, how long_______________________________________ 
              I6: If No, reason capture text_________________________________    
                  
J: Date of current TB diagnosis      ______________________________________________ 
             J1: How was the TB diagnosed Sputum Yes (1) No (0)   CXR Yes (1) No (0)  
                        Abd USS Yes (1) No (0)   FNAB Yes (1) No (0) CSF Yes (1) No (0) Other capture  
                        text   _________________________________________   
             J2: Sensitivity testing Yes (1) No (0)    
             J3: If Yes, Was it MDR Yes (1) No (0) Monoresistance Yes (1)   No (0)  
                        Nonresistance Yes (1) No (0)  
    K: History of developing an IRIS  
             K1: Yes (1) No (0) 
             K2: If yes, specify capture text         ________________________________________________________ 
    L: History of ADRS with current TB treatment 
             L1: Yes (1) No (0) 
             L2: Date of the first symptom of ADR ____________________________________________________ 
             L3: Symptoms: Nausea Yes (1) No (0)     Vomiting Yes (1) No (0)    Itch Yes (1) No (0)     
 
                     General pain Yes (1) No (0)    Sore throat Yes (1) No (0)    Sore eyes Yes (1) No (0)     
 
                     Erythema Yes (1) No (0)   Headache Yes (1) No (0)    Swelling Yes (1) No (0)    Rigors  
 
                    Yes (1) No (0)   Muscle pain Yes (1) No (0)    Abdominal pain Yes (1) No (0)      
                     
                      Diarrhea Yes (1) No (0)     Palpitation Yes (1) No (0)    Fever Yes (1) No (0)   
 







                    L4: History of taking medication 8weeks before the reaction Yes (1) No (0) 
            L5: If Yes, Bactrim Yes (1) No (0)     ARV’S Yes (1) No (0)   anti TB Yes (1) No (0)  
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                  Antibiotics Yes (1) No (0) others capture text      _____________________________________ 
            L6: Date of admission   ____________________________________________ 
            L7: Date of stopping the medication ____________________________________________ 
            L8: Blood results on admission 
                EOS _________    LYMPHOCTE ____________ ALT ______________ AST __________     
                LIPASE ____________   WCC ____________ HB_____________________TOT BILI   ________________       
               CONJ BILI_______________ PLT_______________________ UREA________________ 
               CREATININE___________________HEP A____________   HEP B_______________________ 
                HEP C__________________ EBV_____________________VZV________________ HSV_________________- 
                HHV6______________________________HHV7______________________TOXO_______________ 
 
           L9: Type of current ADR 
      Stevens Johnson syndrome (SJS)    Yes (1) No (0) Toxic epidermal necrolysis    
       (TEN)     Yes (1) No (0) SJS/TEN overlap        Yes (1) No (0)        
       Drug hypersensitivity syndrome (DHS)/ drug reaction with eosinophilia and  
       systemic symptoms (DRESS) Yes (1) No (0)   
       Lichenoid drug reaction       Yes (1) No (0)    Photo induced drug reaction      Yes      
       (1)   No (0)     Fixed drug eruption Yes (1) No (0)   
        Vasculitis         Yes (1) No (0)            AGEP       Yes (1) No (0)         Angioedema         
       Yes (1) No (0)      Morbilliform/exanthematous Yes (1) No (0)   
       Other (capture text)  
      _____________________________________________________________________________________ 
           
M: Current causative TB drugs known:    
             M1: Yes (1)            No (0)     
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             M2: If yes specify drug(s): 
                   Rifampicin Yes (1) No (0)   Isoniazid   Yes (1) No (0)  Pyrazinamide Yes (1) No  
                   (0)     Ethambutol Yes (1) No (0)     streptomycin Yes (1) No (0)               
                   Ethionamide Yes (1) No (0)      Ofloxacin Yes (1) No (0)     Ciprofloxacin Yes (1)  
                   No (0)     Azithromycin Yes (1) No (0)       Amikacin Yes (1) No (0)         
                   Thiacetazone Yes (1) No (0)      Clofazimine Yes (1) No (0)         Clarithromycin Yes  
                   (1) No (0)    kanamycin Yes (1) No (0)    Terizidone Yes (1) No (0)   PAS Yes (1) No  
                   (0)     Cycloserine Yes (1) No (0)            Rifabutin Yes (1) No (0)      
                    Other (capture text) ___________________________________ 
                              
           M3: History of taking backbone drugs Yes (1) No (0) 
           M4: Duration of backbone drugs _____________________________ 
N: Re-challenge of TB medication 
         N1:  Yes (1) No (0) 
         N2: Date of re challenge _______________________________________ 
         N3: Successful re-challenge with the patient on at least anti TB drugs 
                Yes (1) N0 (0) 
        N4: If yes, specify anti Tb drugs             
                Rifampicin Yes (1) No (0) Isoniazid   Yes (1) No (0) Pyrazinamide Yes (1) No  
                (0)     Ethambutol Yes (1) No (0)     streptomycin Yes (1) No (0)               
                Ethionamide Yes (1) No (0)      Ofloxacin Yes (1) No (0)     Ciprofloxacin Yes (1) No  
              (0)     Azithromycin Yes (1) No (0)       Amikacin Yes (1) No (0)         
               Thiacetazone Yes (1) No (0)      Clofazimine Yes (1) No (0)         Clarithromycin Yes   
              (1)  No (0)    kanamycin Yes (1) No (0)    Terizidone Yes (1) No (0)   PAS Yes (1) No  
              (0)     Cycloserine Yes (1) No (0)            Rifabutin Yes (1) No (0)      
              Other (capture text) ___________________________________ 
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          N5: If No, History of ADRS    
 
          N6: Yes (1) No (0) 
 
 
          N7: Symptoms and signs of the re-challenge reactions 
               
                Nausea Yes (1) No (0)     Vomiting Yes (1) No (0)    Itch Yes (1) No (0)     
               
                General pain Yes (1) No (0)    Sore throat Yes (1) No (0)    Sore eyes Yes (1) No (0)       
                Erythema Yes (1) No (0)   Headache Yes (1) No (0)    Swelling Yes (1) No (0)    
                Rigors Yes (1) No (0)   Muscle pain Yes (1) No (0)    Abdominal pain Yes (1) No (0)     
                Diarrhea Yes (1) No (0)     Palpitation Yes (1) No (0)    Fever Yes (1) No (0)   Others  
                capture text   ______________________________________    
 
 
N8: Types of the drug reactions on re-challenge  
          Stevens Johnson syndrome (SJS)    Yes (1) No (0) Toxic epidermal necrolysis    
           (TEN)     Yes (1) No (0) SJS/TEN overlap        Yes (1) No (0)        
           Drug hypersensitivity syndrome (DHS)/ drug reaction with eosinophilia and  
            systemic symptoms (DRESS) Yes (1) No (0)   
           Lichenoid drug reaction       Yes (1) No (0)    Photoinduced drug reaction      Yes      
            (1)   No (0)     Fixed drug eruption Yes (1) No (0)   
            Vasculitis         Yes (1) No (0)            AGEP       Yes (1) No (0)         Angioedema         
            Yes (1) No (0)      Morbilliform/exanthematous Yes (1) No (0)   
            Other (capture text)  
             _____________________________________________________________________________________ 
 
N9: Causative drug known yes (1) no (0) 
              N10:  Specify causative drugs on re challenge 
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                          Rifampicin Yes (1) No (0) Isoniazid   Yes (1) No (0)  Pyrazinamide Yes (1) No  
                          (0) Ethambutol Yes (1) No (0)     streptomycin Yes (1) No (0)               
                          Ethionamide Yes (1) No (0)      Ofloxacin Yes (1) No (0)     Ciprofloxacin Yes (1)     
                          No   (0)     Azithromycin Yes (1) No (0)       Amikacin Yes (1) No (0)         
                           Thiacetazone Yes (1) No (0)      Clofazimine Yes (1) No (0)         Clarithromycin  
                           Yes (1) No (0)    kanamycin Yes (1) No (0)    Terizidone Yes (1) No (0)   PAS  
                           Yes (1) No (0)     Cycloserine Yes (1) No (0)            Rifabutin Yes (1) No (0)      
                           Other (capture text) ___________________________________ 
 
 O: Duration before normalization after re challenge ADRS ______________ 
P1:  Last date of re challenge         _______________________________ 
             P2: Specify anti Tb drugs the patient was discharge with 
                    Rifampicin Yes (1) No (0) Isoniazid   Yes (1) No (0) Pyrazinamide Yes (1) No  
                    (0)     Ethambutol Yes (1) No (0)     streptomycin Yes (1) No (0)               
                    Ethionamide Yes (1) No (0)      Ofloxacin Yes (1) No (0)     Ciprofloxacin Yes (1)  
                    No (0)     Azithromycin Yes (1) No (0)       Amikacin Yes (1) No (0)         
                    Thiacetazone Yes (1) No (0)      Clofazimine Yes (1) No (0)         Clarithromycin  
                    Yes (1) No (0)    kanamycin Yes (1) No (0)    Terizidone Yes (1) No (0)   PAS Yes  
                    (1) No (0)     Cycloserine Yes (1) No (0)            Rifabutin Yes (1) No (0)      
                    Other (capture text) __________________________________ 
 R: Final outcome 
               R1: Completed treatment Yes (1) No (0)    
               R2: If Yes, how long______________________________________ 
               R3: If No, 
               R3:1: still on medications Yes (1) No 0) and for how long ______________________    
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order, without headings  
 Do not include nonstandard abbreviations, acknowledgments of support, or refer to 
footnotes or references  
 Write with a general scientific audience in mind 
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